0001493152-23-027864.txt : 20230811 0001493152-23-027864.hdr.sgml : 20230811 20230811165440 ACCESSION NUMBER: 0001493152-23-027864 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Balance Labs, Inc. CENTRAL INDEX KEY: 0001632121 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 471146785 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-202959 FILM NUMBER: 231164935 BUSINESS ADDRESS: STREET 1: 1111 LINCOLN ROAD STREET 2: 4TH FLOOR CITY: MIAMI STATE: FL ZIP: 33139 BUSINESS PHONE: (305) 907-7600 MAIL ADDRESS: STREET 1: 407 LINCOLN ROAD STREET 2: SUITE 701 CITY: MIAMI BEACH STATE: FL ZIP: 33139 10-Q 1 form10-q.htm
0001632121 false Q2 --12-31 P3Y 2017-04-02 0001632121 2023-01-01 2023-06-30 0001632121 2023-08-11 0001632121 2023-06-30 0001632121 2022-12-31 0001632121 2023-04-01 2023-06-30 0001632121 2022-04-01 2022-06-30 0001632121 2022-01-01 2022-06-30 0001632121 us-gaap:CommonStockMember 2023-03-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001632121 us-gaap:RetainedEarningsMember 2023-03-31 0001632121 2023-03-31 0001632121 us-gaap:CommonStockMember 2022-12-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001632121 us-gaap:RetainedEarningsMember 2022-12-31 0001632121 us-gaap:CommonStockMember 2022-03-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001632121 us-gaap:RetainedEarningsMember 2022-03-31 0001632121 2022-03-31 0001632121 us-gaap:CommonStockMember 2021-12-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001632121 us-gaap:RetainedEarningsMember 2021-12-31 0001632121 2021-12-31 0001632121 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001632121 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001632121 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001632121 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001632121 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001632121 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001632121 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001632121 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001632121 us-gaap:CommonStockMember 2023-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001632121 us-gaap:RetainedEarningsMember 2023-06-30 0001632121 us-gaap:CommonStockMember 2022-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001632121 us-gaap:RetainedEarningsMember 2022-06-30 0001632121 2022-06-30 0001632121 BLNC:EZFillHoldingsIncMember 2020-12-02 2020-12-02 0001632121 BLNC:EZFillHoldingsIncMember 2020-12-02 0001632121 2022-11-17 2022-11-18 0001632121 2022-11-18 0001632121 us-gaap:IPOMember 2022-11-17 2022-11-18 0001632121 BLNC:FirstYearMember BLNC:MonthlyMember us-gaap:IPOMember 2022-11-17 2022-11-18 0001632121 BLNC:SecondYearMember BLNC:MonthlyMember us-gaap:IPOMember 2022-11-17 2022-11-18 0001632121 BLNC:EachAnniversaryMember 2022-11-17 2022-11-18 0001632121 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001632121 BLNC:PharmacyNo27LtdMember 2021-01-29 0001632121 BLNC:PharmacyNo27LtdMember 2023-06-30 0001632121 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001632121 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001632121 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-06-30 0001632121 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-06-30 0001632121 srt:MinimumMember 2023-06-30 0001632121 srt:MaximumMember 2023-06-30 0001632121 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 BLNC:WebsiteMember 2023-06-30 0001632121 BLNC:WebsiteMember 2022-12-31 0001632121 BLNC:ComputerEquipmentAndSoftwareMember 2023-06-30 0001632121 BLNC:ComputerEquipmentAndSoftwareMember 2022-12-31 0001632121 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001632121 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001632121 BLNC:SammyFarkasFoundationIncMember 2019-10-03 0001632121 BLNC:FourAcquisitionsLtdMember 2021-09-30 0001632121 BLNC:FourAcquisitionsLtdMember 2021-09-29 2021-09-30 0001632121 BLNC:FourAcquisitionsLtdMember 2023-01-01 2023-06-30 0001632121 BLNC:FourAcquisitionsLtdMember 2022-01-01 2022-06-30 0001632121 BLNC:FourAcquisitionsLtdMember 2021-01-29 0001632121 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2023-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2022-12-31 0001632121 BLNC:ConvertibleDebentureMember 2016-03-28 2016-04-01 0001632121 BLNC:ConvertibleDebentureMember 2016-04-01 0001632121 BLNC:ConvertibleDebentureMember 2023-06-30 0001632121 BLNC:ConvertibleDebentureMember 2022-12-31 0001632121 BLNC:SammyFarkasFoundationIncMember 2019-10-02 2019-10-03 0001632121 BLNC:ConvertibleDebentureMember us-gaap:RelatedPartyMember 2023-06-30 0001632121 BLNC:ConvertibleDebentureMember us-gaap:RelatedPartyMember 2022-12-31 0001632121 BLNC:ConvertibleDebentureMember 2019-10-02 2019-10-03 0001632121 BLNC:ConvertibleDebentureMember 2019-10-03 0001632121 BLNC:ConvertibleDebentureMember 2023-01-01 2023-06-30 0001632121 BLNC:ConvertibleDebentureMember 2022-01-01 2022-12-31 0001632121 BLNC:BalanceGroupLLCMember 2016-12-31 0001632121 BLNC:BalanceGroupLLCMember 2017-12-31 0001632121 BLNC:BalanceGroupLLCMember 2019-12-31 0001632121 BLNC:BalanceGroupLLCMember 2023-06-30 0001632121 BLNC:BalanceGroupLLCMember 2022-12-31 0001632121 BLNC:SammyFarkasFoundationIncMember 2023-06-30 0001632121 BLNC:SammyFarkasFoundationIncMember 2022-12-31 0001632121 BLNC:PromissoryNoteMember us-gaap:WarrantMember 2019-10-03 0001632121 us-gaap:WarrantMember BLNC:PromissoryNoteMember 2023-01-01 2023-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2021-06-27 0001632121 srt:ChiefExecutiveOfficerMember 2021-06-26 2021-06-27 0001632121 BLNC:BalanceGroupLLCMember 2016-09-30 0001632121 BLNC:BalanceGroupLLCMember 2021-09-30 0001632121 BLNC:BalanceGroupLLCMember 2023-01-01 2023-06-30 0001632121 BLNC:LyonsCapitalLLCMember 2021-07-09 0001632121 BLNC:KryptoVenturesIncMember 2021-07-09 0001632121 BLNC:KryptoVenturesIncMember 2021-07-29 0001632121 BLNC:KryptoVenturesIncMember 2021-06-29 0001632121 BLNC:LyonsCapitalLLCMember 2021-06-29 0001632121 BLNC:KryptoVenturesIncMember 2021-06-28 2021-06-29 0001632121 BLNC:ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001632121 BLNC:ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0001632121 BLNC:NewellTradingGroupMember 2023-01-01 2023-06-30 0001632121 BLNC:BalanceGroupLLCMember 2023-06-30 0001632121 BLNC:BalanceGroupLLCMember 2022-12-31 0001632121 BLNC:FoundationMember 2023-06-30 0001632121 BLNC:FoundationMember 2022-12-31 0001632121 BLNC:ConvertibleDebentureMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure BLNC:Segment utr:sqft BLNC:integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 333-202959

 

BALANCE LABS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   47-1146785

(State or other jurisdiction

Identification No.)

 

(IRS Employer

of incorporation)

 

407 Lincoln Road, Suite 701

Miami Beach, Florida 33139

(Address of principal executive offices)

 

(305) 907-7600

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller Reporting Company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of August 11, 2023, there were 21,674,000 shares outstanding of the registrant’s common stock.

 

 

 

 
 

 

BALANCE LABS, INC.

FORM 10-Q

 

TABLE OF CONTENTS

 

  Page
PART I - FINANCIAL INFORMATION  
   
Item 1. Unaudited Financial Statements. 4
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 18
   
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 24
   
Item 4. Controls and Procedures. 24
   
PART II - OTHER INFORMATION  
   
Item 1. Legal Proceedings. 25
   
Item 1A. Risk Factors. 25
   
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds. 25
   
Item 3 Defaults Upon Senior Securities. 25
   
Item 4. Mine Safety Disclosures. 26
   
Item 5. Other Information. 26
   
Item 6. Exhibits. 26
   
Signatures 27

 

2

 

 

Explanatory Note:

 

The registrant has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, however, the registrant is not subject to such fling requirements and is making such filings on a voluntary basis.

 

3

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Balance Labs, Inc.

Consolidated Balance Sheets

 

   June 30, 2023   December 31, 2022 
   (Unaudited)     
         
Assets          
           
Current Assets          
Cash and cash equivalents  $182,400   $235,311 
Accounts receivable   -    45,000 
Marketable securities   

155,452

    148,808 
           
Total Current Assets   

337,852

    429,119 
           
Total Assets  $337,852   $429,119 
           
Liabilities and Stockholders’ Deficit          
           
Current Liabilities          
Accounts payable and accrued expenses  $1,307,113   $1,220,017 
Accounts payable - related party   911,659    911,659 
Short -term advances - related party   1,673,558    1,673,558 
Convertible note payable   25,000    25,000 
Convertible notes payable - related party, net of debt discount of $0 and $0, as of June 30, 2023 and December 31, 2022   173,192    173,192 
Notes payable - related party - net of debt discount of $0 and $0 as of June 30, 2023 and December 31, 2022   106,850    106,850 
           
Total Current Liabilities   

4,197,372

    4,110,276 
           
Long Term Liabilities          
Convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022   

485,825

    480,155 
Total Long-Term Liabilities   

485,825

    480,155 
           
Total Liabilities   

4,683,197

    4,590,431 
           
Commitments and Contingencies (Note 8)   -    - 
           
Stockholders’ Deficit          
Preferred stock, $0.0001 par value, 50,000,000 shares authorized, none issued and outstanding as of June 30, 2023 and December 31, 2022   -    - 
Common stock, $0.0001 par value: authorized 500,000,000, 21,674,000 and 21,674,000 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively   2,167    2,167 
Additional paid-in capital   810,048    810,048 
Accumulated deficit   

(5,157,560

)   (4,973,527)
           
Total Stockholders’ Deficit   

(4,345,345

)   (4,161,312)
           
Total Liabilities and Stockholders’ Deficit  $337,852   $429,119 

 

The accompanying condensed notes are an integral part of the unaudited consolidated financial statements

 

4

 

 

Balance Labs, Inc.

Consolidated Statements of Operations

(Unaudited)

 

   2023   2022   2023   2022 
  

For the Three Months

Ended June 30,

  

For the Six Months

Ended June 30,

 
   2023   2022   2023   2022 
                 
Revenues - related party  $-   $67,500   $-   $135,000 
                     
Costs and expenses                    
General and administrative expenses   

7,725

    7,256    

11,531

    11,295 
Professional fees   

20,193

    31,248    

38,975

    75,460 
Salaries and wages   

13,252

    10,529    

26,941

    33,821 
General and administrative expenses - related party   

-

    30,000    

-

    60,000 
Total operating expenses   

41,170

    79,033    

77,447

    180,576 
                     
Loss from operations   

(41,170

)   (11,533)   

(77,447

)   (45,576)
                     
Other income (expense)                    
Unrealized gain (loss) on available for sale securities   

1,329

    (99,649)   

6,644

    (231,184)
Proceeds from sale of investment   

-

    -    

    287 
Net loss allocated from equity method investees   -    (41,102)   -    (47,256)
Accreted interest income and interest income on note receivable   

-

    3,473    

-

    10,997 
Interest expense (includes amortization of debt discount)   

(56,912

)   (58,616)   

(113,230

)   (116,657)
Total other (expense)   

(55,583

)   (195,894)   

(106,586

)   (383,813)
                     
Net loss  $

(96,753

)  $(207,427)  $

(184,033

)  $(429,389)
                     
Net Loss per share - basic and diluted  $

(0.00

)  $(0.01)   

(0.01

)  $(0.02)
                     
Weighted average number of shares - basic and diluted   21,674,000    21,674,000    21,674,000    21,674,000 

 

The accompanying condensed notes are an integral part of the unaudited consolidated financial statements

 

5

 

 

Balance Labs, Inc.

Consolidated Statements of Changes in Stockholders’ Deficit

For the Three and Six Months Ended June 30, 2023

(Unaudited)

 

   Shares   Amount   Capital   Deficit   Deficit 
           Additional       Total 
   Common Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit   Deficit 
                     
Balance, March 31, 2023   21,674,000   $2,167   $810,048   $

(5,060,807

)  $4,248,592 
                          
Net loss   -    -    -    (96,753)   (96,753)
                          
Balance, June 30, 2023   21,674,000   $2,167   $810,048   $(5,157,560)  $(4,345,345)
                          
Balance, December 31, 2022   21,674,000   $2,167   $810,048   $(4,973,527)  $(4,161,312)
                          
Net loss   -    -    -    (184,033)   (184,033)
                          
Balance, June 30, 2023   21,674,000   $2,167   $810,048   $(5,157,560)  $

(4,345,345

)

 

Balance Labs, Inc.

Consolidated Statements of Changes in Stockholders’ Deficit

For the Three and Six Months Ended June 30, 2022

(Unaudited)

 

           Additional       Total 
   Common Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit   Deficit 
                     
                     
Balance, March 31, 2022   21,674,000   $2,167   $810,048   $(4,427,138)  $(3,614,923)
                          
Net loss   -    -    -    (207,427)   (207,427)
                          
Balance, June 30, 2022   21,674,000   $2,167   $810,048   $(4,634,565)  $(3,822,350)
                          
Balance, December 31, 2021   21,674,000   $2,167   $810,048   $(4,205,176)  $(3,392,962)
                          
Net loss   -    -    -    (429,389)   (429,389)
                          
Balance, June 30, 2022   21,674,000   $2,167   $810,048   $(4,634,565)  $(3,822,350)

 

The accompanying condensed notes are an integral part of the unaudited consolidated financial statements

 

6

 

 

Balance Labs, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

   2023   2022 
   For the Six Months Ended June 30, 
   2023   2022 
Operating activities          
Net loss  $(184,033)  $(429,389)
Adjustments to reconcile net loss to net cash used in operations          
Amortization of debt discount   5,670    9,098 
Accreted interest on note receivable   -    (3,308)
Net loss from equity method investment   

-

    46,030 
Unrealized (gain) loss on available - for - sale securities   

(6,644

)   231,183 
Changes in operating assets and liabilities          
Decrease (Increase) in          
Accounts receivable – related party   

45,000

    (22,500)
Interest receivable   -    (7,690)
Increase in          
Accounts payable and accrued expenses   

87,096

    115,561 
Accounts payable and accrued expenses - related party   -    60,000 
Accumulated losses on unconsolidated investees in excess of investment   -    1,226 
Net cash used in operating activities   

(52,911

)   211 
           
Net decrease in cash and cash equivalents   

(52,911

)   211 
           
Cash and cash equivalents - beginning of period   

235,311

    227,558 
           
Cash and cash equivalents - end of period  $182,400   $227,769 
           
Supplemental disclosure of cash flow information          
Cash paid for interest  $-   $- 
Cash paid for income tax  $-   $- 
           
Supplemental disclosure of non-cash investing and financing activities          
           
Investment at fair value received from issuance of note receivable  $-   $- 

 

The accompanying condensed notes are an integral part of the unaudited consolidated financial statements

 

7

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Note 1 – Business Organization and Nature of Operations

 

Balance Labs, Inc. (“Balance Labs” or the “Company”) was incorporated on June 5, 2014, under the laws of the State of Delaware. Balance Labs is a consulting firm that provides business development and consulting services to start up and development stage businesses. The Company seeks to offer services to help businesses in various industries improve and fine tune their business models, sales and marketing plans and internal operations as well as make introductions to professional services such as business plan writing, accounting firms and legal service providers.

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial position of Balance Labs as of June 30, 2023, and the unaudited consolidated results of its operations and cash flows for the six months ended June 30, 2023. The unaudited consolidated results of operations for the six months ended June 30, 2023, are not necessarily indicative of the operating results for the full year. It is recommended that these unaudited consolidated financial statements be read in conjunction with the audited financial statements and related disclosures of the Company for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on April 17, 2023.

 

Note 2 – Going Concern

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company used $52,911 of cash in operating activities during the six months ended June 30, 2023, and currently has $182,400 in cash as of June 30, 2023. Additionally, at June 30, 2023, the Company had an accumulated deficit of $5,157,560 and a working capital deficit of $3,859,520.

 

There is substantial doubt about the Company to continue as a going concern for a period of twelve months from the date of these financial statements were made available. The Company without additional sources of debt or equity capital would potentially need to cease operations. Management plans to seek to raise additional capital within the next twelve months that is expected to sustain its operations for the next year. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing. In addition, the Company expects to begin a marketing campaign to market and sell its services. There can be no assurance that such a plan will be successful.

 

The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

Note 3 – Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of 90 days or less to be cash equivalents. At June 30, 2023, and December 31, 2022, the Company has $2,000 in cash equivalents, respectively.

 

8

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts by specific customer identification. If market conditions decline, actual collections may not meet expectations and may result in decreased cash flow and increased bad debt expense. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.

 

Revenue Recognition

 

The Company accounts for its revenues under FASB ASC 606, which is a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company considers revenue realized or realizable and earned when all the five following criteria are met: (1) Identify the Contract with a Customer, (2) Identify the Performance Obligations in the Contract, (3) Determine the Transaction Price, (4) Allocate the Transaction Price to the Performance Obligations in the Contract, and (5) Recognize Revenue When (or As) the Entity Satisfies a Performance Obligation.

 

The Company recognizes consulting income when the services are performed, and performance obligations are satisfied over time or point of time.

 

Income Taxes

 

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.

 

The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

 

9

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Management has evaluated and concluded that there are no material tax positions requiring recognition in the Company’s unaudited condensed consolidated financial statements as of June 30, 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s 2020, 2021, and 2022 tax returns remain open for audit for Federal and State taxing authorities.

 

The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statement of operations.

 

Marketable Securities

 

The Company accounts for marketable and available-for-sale securities under ASU 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income.

 

The Company accounts for its investment in EZFill Holdings, Inc. as available-for-sale securities pursuant to the S-1 Registration Statement declared effective on September 14, 2021, therefore, the unrealized gain (loss) on the available-for-sale securities during the six months ended June 30, 2023, and 2022 has been recorded in Other Income.

 

On December 2, 2020, the Company received 1,000,000 shares from EZFill Holdings, Inc, a related party, for past services, with each share valued at $1 each. At the time of acquiring these shares, EZFill Holdings, Inc. was not a publicly traded company.

 

On September 14, 2021, the S-1 Registration Statement for EZFill Holdings, Inc. was declared effective by the U.S. Securities and Exchange Commission. As a result of becoming a publicly traded company, our investment is now recorded at fair value as available-for-sale securities on June 30, 2023, with the gains and losses being recorded through other income on the consolidated statements of operations for the three then ended.

 

On November 18, 2020, the Company executed a two (2) year, third-party consulting agreement for various corporate services. The current service agreement has expired effective November 18, 2022. In connection with this agreement, and with the effectiveness of the Company’s Form S-1 registration statement, the Company was entitled to compensation as follows:

 

1,000,000 shares of common stock having a fair value of $1,000,000 ($1.00/share), each based on a recent cash price of the related party;

● a single payment of $200,000;

● during the first year of the agreement, $25,000 per month, with the 1st payment due 30 days after the completion of the Company’s IPO;

● during the second year of the agreement, $22,500 per month; and

● on each anniversary of the agreement, 500,000 shares of common stock.

 

At June 30, 2023, the Company owned 66,432 shares and the fair value of the investment in EZFill Holdings, Inc. was reported on the balance sheet as Investment at fair value - related party totaling $155,452 ($2.34/share). The Company recorded an adjustment of $6,644 for the six months ending June 30, 2023, as unrealized gain on securities. EZFill Holdings Inc. reported a 1 share for 8 share reverse stock split on April 26, 2023, which affected the total number of shares reported as of June 30, 2023.

 

10

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Investments – Related Parties

 

When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein.

 

The Company holds one investment as of June 30, 2023, and one investment as of December 31, 2022.

 

Investments

 

On January 29, 2021, the Company received 20% ownership of Pharmacy No, 27, Ltd, a company based in Israel, as part of a Note Receivable from a third party (see Note 5). As of June 30, 2023, the investment has a fair value of $0, based upon the quoted closing trading price and it is recorded on our consolidated balance sheet using the equity method. During each six months ended June 30, 2023, the Company recorded $0 of unrealized loss from this investment.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2023, and December 31, 2022, the carrying value of marketable securities was $155,452 and $148,808, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).

 

Principles of Consolidation

 

The consolidated financial statements include the Company and its wholly owned corporate subsidiaries, Balance Labs LLC., from October 12, 2015, Balance AgroTech Co., from July 11, 2016, Advanced Auto Tech Co., from May 10, 2016, Balance Cannabis Co., from May 13, 2016, and Balance Medical Marijuana Co from December 22, 2015. All intercompany transactions are eliminated. The Company’s four subsidiaries, Balance AgroTech Co., Advanced AutoTech Co., Balance Cannabis Co., and Balance Medical Marijuana Co. are dormant.

 

11

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Net Income (Loss) Per Common Share

 

Basic and diluted income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and warrants from convertible debentures outstanding during the periods. The effect of 0 and 40,000 warrants and 3,698,494 and 3,526,378 shares from convertible notes payable for the six months ended June 30, 2023, and 2022, respectively.

 

Stock-Based Compensation

 

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees.

 

The Company has computed the fair value of warrants granted using the Black-Scholes option pricing model. The expected term used for warrants is the contractual life. Since the Company’s stock has not been publicly traded for a sufficiently long period, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

 

Fair Value of Financial Instruments

 

The Company measures its financial assets and liabilities in accordance with GAAP. For certain of our financial instruments, including cash, accounts payable, and the short-term portion of long-term debt, the carrying amounts approximate fair value due to their short maturities.

 

We adopted accounting guidance for financial and non-financial assets and liabilities (ASC 820). This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

 

12

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2023.

  

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $155,452   $155,452   $     -   $     - 
Total Assets measured at fair value  $155,452   $155,452   $-   $- 

 

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2022.

 

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $148,808   $148,808   $      -   $      - 
Total Assets measured at fair value  $148,808   $148,808   $-   $- 

 

The Company accounts for its investment in EzFill Holdings, Inc. (“EzFill”) as available-for-sale securities. Since the investment is valued based on quoted market price using observable inputs.

 

Business Segments

 

The Company operates in one segment and therefore segment information is not presented.

 

Advertising, Marketing and Promotional Costs

 

Advertising, marketing, and promotional expenses are expensed as incurred and are included in selling, general and administrative expenses on the accompanying unaudited condensed consolidated statement of operations. For the six months ended June 30, 2023, and June 30, 2022, advertising, marketing, and promotion expense was $2,394 and $48, respectively.

 

Property and equipment

 

Property and equipment consist of furniture and office equipment and is stated at cost less accumulated depreciation. Depreciation is determined by using the straight-line method for furniture and office equipment, over the estimated useful lives of the related assets, generally three to five years.

 

Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the related assets.

 

13

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Property and equipment as of June 30, 2023, and December 31, 2022 consisted of the following:

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
Website  $1,336   $1,336 
Computer equipment & Software   5,358    5,358 
Furniture   4,622    4,622 
Total   11,316    11,316 
Less Accumulated Depreciation   (11,316)   (11,316)
Property and Equipment, net  $-   $- 

 

Depreciation expense for the six months ended June 30, 2023, and 2022 totaled $0 and $0, respectively.

 

Recently Issued Accounting Pronouncements

 

The Company has evaluated all new accounting standards that are in effect and may impact its unaudited condensed consolidated financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.

 

Note 4 – Stockholders’ Equity

 

Authorized Capital

 

The Company is authorized to issue 500,000,000 shares of common stock, $0.0001 par value, and 50,000,000 shares of preferred stock, $0.0001 par value.

 

Warrants

 

On October 3, 2019, the Company received $40,000 from The Sammy Farkas Foundation in exchange for a promissory note which bears 12% interest per annum and matured on October 10, 2020, or upon the Company raising $500,000 from outside investors, whichever occurs first. In conjunction with The Sammy Farkas Foundation agreement the Company issued warrants to purchase 40,000 shares of the Company’s common stock at an exercise price of $1.00 per share which expired on October 10, 2022. As of June 30, 2023, there are no warrants outstanding.

 

14

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Note 5 – Note Receivable

 

On September 30, 2021, Balance Labs Inc. made a loan to Four Acquisition, Ltd., an unrelated party in the principal amount of $22,000 which loan has an interest rate of 10% per annum and a maturity date of September 30, 2022. As of June 30, 2023, this receivable is fully reserved against. For the six months ended June 30, 2023 and 2022, the Company recorded $0 and $0, respectively, of interest income in relation to this note.

 

On January 29, 2021, Balance Labs Inc. made a loan to Four Acquisitions Ltd., an unrelated party in the principal amount of $119,000 which has an interest rate of 10% per annum and a maturity date of January 28, 2022. Additionally, in connection with the loan, the Company received a 20% interest in the recently acquired business and related assets of Four Acquisitions Ltd. Initially, this investment had a purchase price of $43,000, which was recorded as a discount from the note which will be amortized over the life of the note. The Company recorded an allowance of 100% against this receivable of $141,000 as of June 30, 2023.

 

Note 6 – Related Party Transactions

 

The Company’s CEO earned $10,000 per month through June 30, 2022. This agreement was terminated effective June 30, 2022. The following compensation was recorded within general and administrative expenses – related parties on the statements of operations: $0 and $30,000 for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and December 31, 2022, $0 and $30,000, respectively, of compensation was unpaid and was included in accounts payable – related party on the consolidated balance sheets.

 

On April 1, 2016, the Company received $500,000 from Newell Trading Group in exchange for a convertible debenture due April 2, 2017, bearing interest at 10% and convertible into common stock at $.25 per share unless the note is paid by the Company prior to the election of the holder to convert. The Company recognized a beneficial conversion feature expense of $500,000 that has been fully amortized. As of June 30, 2023 and December 31, 2022, accrued interest on the note is $350,000 and $300,000, respectively. On October 3, 2019, Newell Trading Group assigned its rights and interests in its $500,000 convertible debenture to the Sammy Farkas Foundation Inc., (the “Foundation”), a related party. The convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022 of $485,825 and $480,155, respectively was recorded under long term liability on the balance sheet.

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
16th Avenues Associates  $500,000   $500,000 
Debt discount   (14,175)   (19,845)
Convertible note payable – long term  $485,825   $480,155 

 

The Foundation then entered into an agreement with the Company to extend the maturity date of the convertible debenture to October 10, 2024 in exchange for 54,000 shares of the Company’s stock. The shares have a fair value of $56,700 which was recorded as a debt discount and was being amortized over the life of the extension. On November 11, 2019, The Sammy Farkas Foundation transferred all the rights and interests of the note to another party, 16th Avenue Associates, a non-related party company. The terms remain the same and the transfer has no effect on the financial statements. During the six months ended June 30, 2023 and December 31, 2022, the Company amortized $5,670 and $5,670, respectively of debt discount.

 

During 2016, 2017, and 2019 Balance Group LLC loaned an additional $66,850 to the Company. The notes are in default and have an accrued interest balance of $29,481. The note balance of $66,850 is included in the note payable – related party in current liability as of June 30, 2023 and December 31, 2022.

 

15

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

On October 3, 2019, the Company received $40,000 from The Foundation in exchange for a promissory note which bears 12% interest per annum and matured on October 10, 2020 or upon the Company raising $500,000 from outside investors, whichever occurs first. The promissory note is currently in default, and as of June 30, 2023, accrued interest on the note is $20,818. The note balance of $40,000 is included in the note payable – related party in current liability as of June 30, 2023 and December 31, 2022.

 

The promissory note comes with a warrant to purchase 40,000 shares of the Company’s stock with an exercise price of $1.00 per share and expired on October 10, 2022. The warrants had a relative fair value of $8,283, which was recorded as a debt discount and fully amortized.

  

   June 30,
2023
(unaudited)
   December 31,
2022
 
Balance Group LLC  $66,850   $66,850 
The Foundation   40,000    40,000 
Note Payable – related party  $106,850   $106,850 

 

On June 27, 2021, the Company received $50,000 from the CEO in exchange for a convertible promissory note with a face value of $53,192 which bears 12% interest per annum and matures on June 27, 2022, or upon the Company raising $250,000 from investors, whichever occurs first. The note balance of $53,192 is included in the convertible notes payable - related party, net of debt discount of $0 and $3,428, as of June 30, 2023, and December 31, 2022, respectively. The difference between the amount received and the face value of $3,192 was recorded as a discount and is being amortized over the life of the note. Additionally, the note comes with a beneficial conversion feature of $3,799 which was also recorded as a component of equity in 2021. As of June 30, 2023, the Company has accrued interest of $12,801 and is recorded in the accrued expenses on the balance sheet.

 

On September 30, 2016, Balance Group LLC loaned $120,000 as a convertible note payable to the Company at an interest rate of 10%, due on October 1, 2017. In addition, the Company issued 600,000 warrants at an exercise price of $1 which expired on September 30, 2021 (See Note 9). The note is currently in default and is currently recorded under convertible payable – related party in current liabilities in the balance sheet. The accrued interest balance of $81,008 is recorded in the accrued expenses on the balance sheet as of June 30, 2023.

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
Balance Group LLC  $120,000   $120,000 
Note Payable from CEO   53,192    53,192 
Convertible note payable- related party  $173,192   $173,192 

 

On July 9, 2021, Krypto Ventures, Inc. formerly known as KryptoBank Co. issued an unsecured promissory note in the amount of $25,000 to Lyons Capital LLC, a significant shareholder of Krypto Ventures, Inc. The note carries an interest rate of 12% and is due on the earlier of July 8, 2022, or the date on which Krypto Ventures, Inc. raises at least $200,000. As of July 29, 2021, the Company has accrued interest of $164. The note and accrued interest were deconsolidated as part of deconsolidation of Krypto Ventures, Inc.

 

On June 29, 2021, Balance Labs Inc. made a loan to Krypto Ventures, Inc, formerly known as KryptoBank Co., a related party in the principal amount of $25,000 which loan has an interest rate of 12% per annum and a maturity date of June 28, 2022.

 

As of June 30, 2023 and December 31, 2022, the CEO and companies controlled by the CEO have loaned the Company a total of $1,673,558 in addition to the convertible notes discussed above. The loans carry an interest rate of 8% and mature one year and one day from the date of the loan. These loans of $1,673,558 and the accrued interest on these loans of $418,111 are in default as of June 30, 2023. These loans of $1,673,558 are in default and are reported under short -term advances from related party on the balance sheet as of June 30, 2023 and December 31, 2022.

 

Note 7 – Convertible Notes and Notes Payable

 

Notes Payable

 

For all information regarding the related party note payable see note 6.

 

16

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Convertible Notes Payable

 

On April 1, 2016, the Company received $500,000 from Newell Trading Group in exchange for a convertible debenture due April 2, 2017, bearing interest at 10% and convertible into common stock at $.25 per share unless the note is paid by the Company prior to the election of the holder to convert. The Company recognized a beneficial conversion feature expense of $500,000 that has been fully amortized. As of December 31, 2021, accrued interest on the note is $287,671. On October 3, 2019, Newell Trading Group assigned its rights and interests in its $500,000 convertible debenture to the Sammy Farkas Foundation Inc., (the “Foundation”), a related party. The Foundation then entered into an agreement with the Company to extend the maturity date of the convertible debenture to October 10, 2024 in exchange for 54,000 shares of the Company’s stock. The shares have a fair value of $56,700 which was recorded as a debt discount and amortized over the life of the extension. On November 11, 2019, The Sammy Farkas Foundation transferred all the rights and interests of the note to another party, 16th Avenue Associates. The terms remain the same and the transfer has no effect on the financial statements. The convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022 was $485,825 and $480,155, respectively, and was recorded under long term liability on the balance sheet.

  

   June 30,
2023
(unaudited)
   December 31,
2022
 
Newell Trading Group  $500,000   $500,000 
Debt discount   (14,175)   (19,845)
Convertible note payable – long term  $485,825   $480,155 

 

Note 8 – Commitments and Contingencies

 

Litigation, Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s condensed consolidated financial position or results of operations.

 

17

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis of the condensed consolidated results of operations and financial condition of Balance Labs, Inc., and subsidiaries (“Balance Labs” or the “Company”) for the six months ended June 30, 2023 should be read in conjunction with our condensed consolidated financial statements and the notes thereto that are included elsewhere in this Quarterly Report on Form 10-Q. References in this Management’s Discussion and Analysis of Financial Condition and Results of Operations to “us,” “we,” “our,” and similar terms refer to Balance Labs. This Quarterly Report includes forward-looking statements, as that term is defined in the federal securities laws, based upon current expectations that involve risks and uncertainties, such as plans, objectives, expectations, and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. Words such as “anticipate,” “estimate,” “plan,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions are used to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of certain risk factors discussed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

Overview

 

We were incorporated on June 5, 2014, under the laws of the State of Delaware. We are a consulting firm that provides business development and consulting services to start-up and development-stage companies. Our business model is to provide businesses in various industries with customized consulting services to meet their business needs and help them improve their business models, sales and marketing plans and internal operations, as well as introduce these businesses to experienced professional contacts that would be vital to the success of these companies.

 

The Company is not a registered investment company under the Investment Company Act of 1940, as amended (the “1940 Act”) and does not engage primarily, in the business of investing, reinvesting, or trading in securities. The Company is not managed like an active investment vehicle, is not an investment company registered under the 1940 Act and is not required to register under the 1940 Act.

 

Additionally, in accordance with the 1940 Act, Section 3€(1), the Company is not an Investment Company as defined by the 1940 Act because the Company does not have outstanding securities beneficially owned by more than one hundred persons and, at this time, the Company is not making and does not presently propose to make a public offering of its securities. Additionally, the Company has not and has no plans to purchase or acquire any securities issued by any registered investment company.

 

18

 

 

Our business focuses on providing advisement services to entrepreneurs and assisting business owners so that their ideas can be fully developed and implemented. Due to limited resources, lack of experienced management and competing priorities, start-up and developmental stage companies are not operating as efficiently as they can be, and therefore would benefit from an outside party that could assist in developing and executing certain strategies. We utilize our knowledge in developing businesses, share practical experiences with our clients and introduce the business owners to experienced professionals who could help these inexperienced entrepreneurs further implement their ideas. Start-ups and development stage businesses across all industries commonly experience these certain “growing pains”.

 

Plan of Operations

 

Our plan is to prepare our clients for the many inevitable challenges they will encounter and to develop a customized plan for them to overcome these obstacles, so that they can focus on marketing their product(s) and/or service(s) to their potential customers.

 

Although we’ve only worked with three clients since inception, our goal is to add and service a minimum of two to three new clients between now and the end of 2023. We’re marketing our services through both personal contact and online by (a) mining our existing network of professional contacts via personal outreach programs, which will also target international prospects that may wish to enter the US market; (b) expanding our network by attending targeted conferences and professional gatherings; and (c) utilizing our website at www.balancelabs.co, plus engaging potential clients on social media, including LinkedIn, Facebook and Twitter. However, because we have a limited budget allocated for an on-line marketing campaign, we anticipate that professionals within our professional network and personal referrals from companies that are satisfied with our professional services are likely to be our most significant and efficient near-term form of marketing.

 

We believe that we can support our clients with our existing full-time staff, supplemented with part-time sub-contracted professionals and service providers, as necessary. Between now and the end of 2023, we intend to formalize our relationships with these subcontractors so that we can offer our clients turn-key business development products and services.

 

Our primary requirement for funding is for working capital in order to accommodate temporary negative cash flows from operations (see “Liquidity and Capital Resources”).

 

19

 

 

Results of Operations

 

Three Months Ended June 30, 2023 Compared with Three Months Ended June 30, 2022.

 

Overview

 

We reported a net loss of $96,753 and of $207,427 for the three months ended June 30, 2023 and 2022, respectively. This represents a difference of $110,674, or 53.3%, primarily due to decreases in revenues from related party and decrease of unrealized loss of available for sale securities.

 

Revenues - Related Party

 

For the three months ended June 30, 2023 and June 30, 2022, we generated $0 and $67,500, respectively in revenue. The primary reason for the decrease in revenue was due to expired consulting agreement with EZFill Holdings, Inc. Our president, CEO, CFO and Chairman of the Board is also the former president of EZFill Holdings, Inc. and owns approximately 24% of EZ Fill’s outstanding common stock as of June 30, 2023.

 

General and Administrative Expenses

 

General and administrative expenses were $7,725 and $7,256 for the three months ended June 30, 2023 and 2022, respectively, an increase of 469 or .06% primarily due to an increase in advertising and promotion expense.

 

Professional Fees

 

Professional fees were $20,193 and $31,248 for the three months ended June 30, 2023 and 2022, respectively, a decrease of $11,055 or 54% due to decrease in accounting and legal fees for the quarter.

 

Other Income and Expense

 

Other expenses for the three months ended June 30, 2023 was $55,583. Other expense for the three months ended June 30, 2022 was $195,894. This represents a difference of $140,311 which was attributable to an unrealized loss from available for sale securities, net loss allocated from equity method investees and interest expense offset by accreted interest income and interest income on note receivable.

 

Unrealized gain or loss on available for sale securities

 

Unrealized loss on available for sale securities for the three months ended June 30, 2023 was $1,329. Unrealized loss on available for sale securities for the three months ended June 30, 2022 was $99,649. This represents a decrease of $98,320 or 98% attributable to a reduction in the stock price of the securities.

 

Net Loss allocated from Equity Method Investees

 

Net Loss allocated from Equity Method Investee for the three months ended June 30, 2023 and June 30, 2022 was $0 and $41,102, respectively. This represents a decrease of $41,102 or 100.0% primarily due to decreases in operating expenses by the investees.

 

Six Months Ended June 30, 2023 Compared with Six Months Ended June 30, 2022.

 

Overview

 

We reported a net loss of $184,033 and of $429,389 for the six months ended June 30, 2023 and 2022, respectively. This represents a difference of $245,356, or 57%, primarily due to an increase in the unrealized loss of available for sale securities in 2022.

 

Revenues - Related Party

 

For the six months ended June 30, 2023 and June 30, 2022, we generated $0 and $67,500, respectively in revenue. The primary reason of the decrease in revenue was due to consulting agreement with EZFill Holdings ending in November 2022. Our president, CEO, CFO and Chairman of the Board is also the former president of EZFill Holdings, Inc.

 

General and Administrative Expenses

 

General and administrative expenses were $11,531 and $11,295 for the six months ended June 30, 2023 and 2022, respectively, a decrease of $236 or 2% primarily due to an increase in office expenses.

 

Professional Fees

 

Professional fees were $38,975 and $75,460 for the six months ended June 30, 2023 and 2022, respectively, an decrease of $36,485 or 48% due to decrease in accounting and legal fees for the quarter.

 

Other Income and Expense

 

Other expenses for the six months ended June 30, 2023 was $106,586. Other expense for the six months ended June 30, 2022 was $383,813. This represents a difference of 72% which was attributable to an unrealized loss from available for sale securities and interest expense, offset by proceeds from sale of investment, accreted interest income and interest income on note receivable.

 

20

 

 

Unrealized gain or loss on available for sale securities

 

Unrealized gain on available for sale securities for the six months ended June 30, 2023 was $6,644. Unrealized loss on available for sale securities for the six months ended June 30, 2022 was $231,184. This represents an increase of $224,540 or 97% attributable to a reduction in the stock price of the securities.

 

Net Loss allocated from Equity Method Investee

 

Net Loss allocated from Equity Method Investee for the six months ended June 30, 2023 and June 30, 2022 was $0 and $47,256, respectively. This represents a decrease of $47,256 or 100% primarily due to decrease in operating expenses by the investee.

 

Liquidity and Capital Resources

 

We measure our liquidity in a number of ways, including the following:

 

   June 30, 2023   December 31, 2022 
   (Unaudited)     
Cash  $182,400   $235,311 
Working capital (deficiency)  $3,859,520   $3,681,157 

 

Availability of Additional Funds

 

Except for the monthly consulting fee to our CEO and Chairman of the Board and the monthly lease of our virtual office, as described elsewhere in this annual report, we currently do not have any material commitments for capital expenditures. We are actively pursuing new client relationships. Even if we were to add a new client(s), due to our current lack of a diversified client base, there could be temporary imbalances between cash receipts and cash operating expenditures, which means that we may need additional capital. The engagement revenues associated with most client engagements will self-fund the in-house and sub-contractor services we need in order to supply products and services to our clients.

 

As of June 30, 2023, the Company had a working capital deficiency of $3,859,520. The Company used cash in operations of $52,911. In addition, the Company is working to manage its current liabilities while it continues to make changes in operations to further improve its cash flow and liquidity position.

 

Net Cash Used in Operating Activities

 

We experienced negative cash flows from operating activities for the six months ended June 30, 2023 and June 30, 2022, in the amount of $52,911 and $13,661, respectively. This was primarily due to a net loss of $184,033 primarily offset by an unrealized gain on the value of an investment by $6,644, change in accounts receivable of $45,000, change in accounts payable and accrued expenses by $87,096, and amortization of debt discount $5,670.

 

21

 

 

Net Cash Used in Investing Activities

 

Net cash used in investing activities during the six months ended June 30, 2023 and June 30, 2022 was $0 and $0, respectively.

 

Net Cash Provided by Financing Activities

 

Net cash provided by financing activities during the six months ended June 30, 2023 and June 30, 2022 was $0 and $0, respectively.

 

Our Auditors Have Issued a Going Concern Opinion

 

The Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern as of June 30, 2023. The unaudited condensed consolidated financial statements in this report on Form 10-Q have been prepared assuming that the Company will continue as a going concern. As discussed in the notes to the unaudited condensed consolidated financial statements, these conditions raise substantial doubt from the Company’s ability to continue as a going concern. The Company’s plans in regard to these matters are also described in the notes to the Company’s unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

 

If the Company is unable to meet its internal revenue forecasts or obtain additional financing on a timely basis, it may have to delay vendor payments and/or initiate cost reductions, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately it could be forced to discontinue the Company’s operations, liquidate, and/or seek reorganization under the U.S. bankruptcy code. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.

 

Furthermore, COVID-19 has also caused severe disruptions in transportation and limited access to the Company’s facilities resulting in limited support from its staff and professional advisors. This in turn has limited the Company’s resources in promoting its services and acquiring additional capital.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

Critical Accounting Policies and Estimates

 

Use of Estimates

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could materially differ from those estimates.

 

22

 

 

Revenue Recognition

 

The Company accounts for revenues under FASB ASC 606, which is a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company considers revenue realized or realizable and earned when all the five following criteria are met: (1) Identify the Contract with a Customer, (2) Identify the Performance Obligations in the Contract, (3) Determine the Transaction Price, (4) Allocate the Transaction Price to the Performance Obligations in the Contract, and (5) Recognize Revenue When (or As) the Entity Satisfies a Performance Obligation.

 

Fair Value of Financial Instruments

 

The Company measures its financial assets and liabilities in accordance with GAAP. For certain of our financial instruments, including cash, accounts payable, and the short-term portion of long-term debt, the carrying amounts approximate fair value due to their short maturities.

 

We adopted accounting guidance for financial and non-financial assets and liabilities (ASC 820). This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
   
Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

23

 

 

Recent Accounting Standards

 

We have implemented all new accounting standards that are in effect and may impact our consolidated financial statements and do not believe that there are any other new accounting standards that have been issued that might have a material impact on our financial position or results of operations.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Our management, with the participation of our principal executive officer evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of June 30, 2023.

 

The Company’s assessment identified certain material weaknesses, (i) functional controls, (ii) lack of audit committee and (iii) segregation of duties. Because of the Company’s limited resources, there are limited controls over information processing. The Company does not have an audit committee and therefore there is no independent review and independent oversight over the Company’s financial reporting.

 

There is an inadequate segregation of duties consistent with control objectives. Our Company’s management is composed of a small number of individuals resulting in a situation where limitations on segregation of duties exist. In order to remedy this situation, we would need to hire additional staff to provide greater segregation of duties. Currently, it is not feasible to hire additional staff to obtain optimal segregation of duties. Management will reassess this matter at end of the fiscal year to determine whether improvement in segregation of duty is feasible.

 

Accordingly, as the result of identifying the above material weakness we have concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the Company’s internal controls.

 

24

 

 

Management believes that the material weaknesses set forth above were the result of the scale of our operations and are intrinsic to our small size. Management believes these weaknesses did not have a material effect on our financial results and intends to take remedial actions upon receiving funding for the Company’s business operations.

 

This Quarterly Report on Form 10-Q does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report herein.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

To the best of our knowledge, there are no material pending legal proceedings to which we are a party or of which any of our property is the subject. From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

 

Item 1A. Risk Factors.

 

Not applicable.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

There were no unregistered sales of the Company’s equity securities during the six months ended June 30, 2023.

 

Item 3. Defaults Upon Senior Securities.

 

Notes Payable

 

As of June 30, 2023, the CEO and companies controlled by the CEO have loaned the Company a total of $1,673,558 in addition to the convertible notes discussed above. The loans carry an interest rate of 8% and mature one year and one day from the date of the loan. The Company accrued interest of $418,111 on the loans and $1,673,558 of these loans are in default as of June 30, 2023.

 

Balance Group loaned the Company an additional $66,850 at an interest rate of 8%. The notes are currently in default and have an accrued interest balance of $29,481 as of June 30, 2023.

 

On October 3, 2019, The Company received $40,000 from The Foundation in exchange for a promissory note which bears 12% interest per annum and matured on October 10, 2020 or upon the Company raising $500,000 from outside investors, whichever occurs first. The promissory note is currently in default, and as of June 30, 2023, accrued interest on the note is $20,817. The promissory note comes with a warrant to purchase 40,000 shares of the Company’s stock with an exercise price of $1.00 per share and expires on October 10, 2022. These warrants have expired. As of December 31, 2020, the debt discount was fully amortized.

 

25

 

 

Convertible Notes Payable

 

On December 23, 2015, the Company issued a secured convertible promissory note in the amount of $25,000. The note carries a rate of 8% and was due on March 23, 2016. It is secured by all the assets of the Company. The note further contains a provision that the lender may convert any part of the note, including accrued interest that is unpaid into the Company’s common stock at an exercise price of $0.50 per share. The note also contains a five-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.50 per share until December 23, 2020. As of March 23, 2016, the note is in default and the interest rate has been increased to 18%. The accrued interest balance of $37,732 as of June 30, 2023.

 

On September 30, 2016, Balance Group LLC loaned the Company $120,000 with an interest rate of 10% and is convertible into common stock at $1.00. In addition, the Company issued the CEO 600,000 warrants and recorded a debt discount of $111,428, which has been fully amortized. The Company valued the warrants using the Black-Scholes option pricing model with the following assumptions: Expected volatility of 514%, expected life of five years, risk free rate of return of 1.14% and an expected divided yield of 0%. The warrants had a fair value of $85,714. The note is currently in default and has an accrued interest balance of $81,008 as of June 30, 2023.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits

 

Exhibit No.   Description
     
31.1   Certification of Principal Executive Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 302 of 2002*
31.2   Certification of Principal Financial Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 302 of 2002*
32.1   Certification of Principal Executive Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
32.2   Certification of Principal Financial Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INS   Inline XBRL Instance Document*
101.SCH   Inline XBRL Taxonomy Extension Schema Document*
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*Filed herewith

**Furnished herewith

 

26

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BALANCE LABS, INC.
     
Date: August 11, 2023 By: /s/ Michael D. Farkas
    Michael D. Farkas
   

President, Chief Executive Officer

(Principal Executive Officer)

 

Date: August 11, 2023

By: /s/ Ari Feldman
    Ari Feldman
   

Chief Financial Officer (Principal Financial and

Accounting Officer)

 

27

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Michael D. Farkas, certify that:

 

1. I have reviewed this Form 10-Q of Balance Labs, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s first fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2023

By: /s/ Michael D. Farkas
    Michael D. Farkas
   

President, Chief Executive Officer

(Principal Executive Officer)

    Balance Labs, Inc.

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Ari Feldman, certify that:

 

1. I have reviewed this Form 10-Q of Balance Labs, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s first fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2023

By: /s/ Ari Feldman
    Ari Feldman
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    Balance Labs, Inc.

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report of Balance Labs, Inc. (the “Company”), on Form 10-Q for the period ended June 30, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Michael D. Farkas, Chief Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) Such Quarterly Report on Form 10-Q for the period ended June 30, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in such Quarterly Report on Form 10-Q for the period ended June 30, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 11, 2023

By: /s/ Michael D. Farkas
    Michael D. Farkas
   

President, Chief Executive Officer

(Principal Executive Officer)

    Balance Labs, Inc.

 

 

 

EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report of Balance Labs, Inc. (the “Company”), on Form 10-Q for the period ended June 30, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Ari Feldman, Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) Such Quarterly Report on Form 10-Q for the period ended June 30, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in such Quarterly Report on Form 10-Q for the period ended June 30, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 11, 2023

By: /s/ Ari Feldman
    Ari Feldman
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

    Balance Labs, Inc.

 

 

 

EX-101.SCH 6 blnc-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Organization and Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note Receivable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Convertible Notes and Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Convertible Notes and Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Schedule of Fair Value of Assets on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Convertible Note Payable - Long Term (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Schedule of Note Payable - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Convertible Note Payable - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Convertible Notes and Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 blnc-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 blnc-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 blnc-20230630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Related Party, Type [Axis] EZFill Holdings, Inc, [Member] Sale of Stock [Axis] IPO [Member] Scenario [Axis] First Year [Member] Award Date [Axis] Monthly [Member] Second Year [Member] Each Anniversary [Member] Related Party [Member] Investment, Name [Axis] Pharmacy No 27 Ltd [Member] Warrant [Member] Short-Term Debt, Type [Axis] Convertible Notes Payable [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Long-Lived Tangible Asset [Axis] Website [Member] Computer Equipment & Software [Member] Furniture and Fixtures [Member] Sammy Farkas Foundation Inc. [Member] Business Acquisition [Axis] Four Acquisitions Ltd [Member] Title of Individual [Axis] Chief Executive Officer [Member] Debt Instrument [Axis] Convertible Debenture [Member] Related Party Transaction [Axis] Consolidated Entities [Axis] Balance Group LLC [Member] Promissory Note [Member] Lyons Capital LLC [Member] Krypto Ventures Inc [Member] Chief Executive Officer and Company's Controlled by Chief Executive Officer [Member] Newell Trading Group [Member] Foundation [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current Assets Cash and cash equivalents Accounts receivable Marketable securities Total Current Assets Total Assets Liabilities and Stockholders’ Deficit Current Liabilities Accounts payable and accrued expenses Accounts payable - related party Short -term advances - related party Convertible note payable Convertible notes payable - related party, net of debt discount of $0 and $0, as of June 30, 2023 and December 31, 2022 Notes payable - related party - net of debt discount of $0 and $0 as of June 30, 2023 and December 31, 2022 Total Current Liabilities Long Term Liabilities Convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022 Total Long-Term Liabilities Total Liabilities Commitments and Contingencies (Note 8) Stockholders’ Deficit Preferred stock, $0.0001 par value, 50,000,000 shares authorized, none issued and outstanding as of June 30, 2023 and December 31, 2022 Common stock, $0.0001 par value: authorized 500,000,000, 21,674,000 and 21,674,000 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Deficit Total Liabilities and Stockholders’ Deficit Debt instrument, unamortized discount, current Notes payable - related party, debt discount - current Convertible notes payable, debt discount - long term Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock shares outstanding Income Statement [Abstract] Revenues - related party Costs and expenses General and administrative expenses Professional fees Salaries and wages General and administrative expenses - related party Total operating expenses Loss from operations Other income (expense) Unrealized gain (loss) on available for sale securities Proceeds from sale of investment Net loss allocated from equity method investees Accreted interest income and interest income on note receivable Interest expense (includes amortization of debt discount) Total other (expense) Net loss Net Loss per share - basic Net Loss per share - diluted Weighted average number of shares - basic Weighted average number of shares - diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Operating activities Adjustments to reconcile net loss to net cash used in operations Amortization of debt discount Accreted interest on note receivable Net loss from equity method investment Unrealized (gain) loss on available - for - sale securities Changes in operating assets and liabilities Decrease (Increase) in Accounts receivable – related party Interest receivable Increase in Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Accumulated losses on unconsolidated investees in excess of investment Net cash used in operating activities Net decrease in cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Supplemental disclosure of cash flow information Cash paid for interest Cash paid for income tax Supplemental disclosure of non-cash investing and financing activities Investment at fair value received from issuance of note receivable Accounting Policies [Abstract] Business Organization and Nature of Operations Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Summary of Significant Accounting Policies Equity [Abstract] Stockholders’ Equity Receivables [Abstract] Note Receivable Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Convertible Notes and Notes Payable Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Cash and Cash Equivalents Use of Estimates Accounts Receivable Revenue Recognition Income Taxes Marketable Securities Investments – Related Parties Investments Concentration of Credit Risk Principles of Consolidation Net Income (Loss) Per Common Share Stock-Based Compensation Fair Value of Financial Instruments Business Segments Advertising, Marketing and Promotional Costs Property and equipment Recently Issued Accounting Pronouncements Schedule of Fair Value of Assets on Recurring Basis Schedule of Property and Equipment Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Schedule of Convertible Note Payable - Long Term Schedule of Note Payable - Related Party Schedule of Convertible Note Payable - Related Party Net cash provided (used in) operating activities Cash Accumulated deficit Working capital Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair-value - equity securities Total Assets measured at fair value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Total Less Accumulated Depreciation Property and Equipment, net Cash equivalents Issuance of shares Share price Issuance of value Shares issued price, per share Fair value of investment cost Fair value of investment cost Unrealized loss on securities Reverse stock split description Equity method investment percentage, description Ownership percentage Investments Unrealized loss on investments Marketable securities Antidilutive securities excluded from earnings per share amount Number of operating segment Advertising, marketing and promotion expense Property, plant and equipment, estimated useful life Depreciation Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Debt instrument, face amount Interest rate of related party loan Due to related parties Warrants issued to purchase of common stock shares Warrants exercise price per share Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Debt instrument face amount Debt instrument interest rate stated percentage Debt maturity date Interest income related party Equity interest acquire percentage Investments fair value disclosure Notes receivable unamortized allowance current, percentage Notes receivable unamortized allowance current Convertible note payable – long term, gross Debt discount Convertible note payable – long term Note Payable – related party Convertible note payable- related party Officers compensation General and administrative expenses - related party Accounts payable related party Proceeds from convertible debt Debt instrument convertible conversion price Debt instrument, convertible, beneficial conversion Interest payable current and noncurrent Debt instrument, increase (decrease), net Debt instrument discount Long term debt Debt instrument maturity rate Number of shares exchange Debt instrument unamortized discount Convertible notes payable Convertible notes payable Class of warrants Fair value of warrants Debt instrument maturity date Number of warrants issued to related party Accrued interest Unsecured debt Financing Receivable, after Allowance for Credit Loss Short-term advances from related party Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Proceeds from Convertible Debt Debt Instrument, Maturity Date Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Convertible, Conversion Price Debt Instrument, Convertible, Beneficial Conversion Feature Interest Payable Debt Instrument, Increase (Decrease), Net Debt instrument, extended maturity date Debt Instrument, Unamortized Discount, Noncurrent Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount (Premium), Net Accounts payable related party current. Short-term advances - related party. Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer). Notes payable unamortized discount current. Selling general and administrative expenses related and nonrelated party. Accreted Interest Income And Interest Income On Note Receivable. Accreted interest on note receivable. Equity method investment summarized financial Information net loss. Accumulated (income) losses on unconsolidated investees in excess of investment. Investment at fair value received from issuance of note receivable. Working capital deficit. EZFill Holdings, Inc, [Member]. First Year [Member] Monthly [Member] Second Year [Member] Each Anniversary [Member] Disclosure of accounting policy for investment related parties. Equity method investment percentage, description. Pharmacy No 27 Ltd [Member] Unrealized loss on investments. KryptoBank Co. [Member] Krypto Ventures Inc [Member]. Sammy Farkas Foundation Inc [Member] Four Acquisitions Ltd [Member]. Notes receivable unamortized allowance current. Notes receivable unamortized allowance current, percentage. Convertible Debenture [Member]. Newell Trading Group [Member] Debt instrument, Extended maturity date. Number of shares exchange. Balance Group LLC [Member]. Promissory Note [Member]. Number of warrants issued to related party. Lyons Capital LLC [Member]. Chief Executive Officer And Company's Controlled By Chief Executive Officer [Member]. Convertible Notes Payable Related Party [Table Text Block] Website [Member] Computer Equipment & Software [Member] Foundation [Member] Assets, Current Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Liabilities Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Shares, Outstanding AccretedInterestOnNoteReceivable Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Increase (Decrease) in Accounts Receivable, Related Parties Increase (Decrease) in Accrued Interest Receivable, Net Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations WorkingCapitalDeficit Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Investment Owned, Cost Investments [Default Label] Marketable Securities [Default Label] Selling, General and Administrative Expense EX-101.PRE 10 blnc-20230630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - shares
6 Months Ended
Jun. 30, 2023
Aug. 11, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 333-202959  
Entity Registrant Name BALANCE LABS, INC.  
Entity Central Index Key 0001632121  
Entity Tax Identification Number 47-1146785  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 407 Lincoln Road  
Entity Address, Address Line Two Suite 701  
Entity Address, City or Town Miami Beach  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33139  
City Area Code (305)  
Local Phone Number 907-7600  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   21,674,000
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 182,400 $ 235,311
Accounts receivable 45,000
Marketable securities 155,452 148,808
Total Current Assets 337,852 429,119
Total Assets 337,852 429,119
Current Liabilities    
Accounts payable and accrued expenses 1,307,113 1,220,017
Accounts payable - related party 911,659 911,659
Short -term advances - related party 1,673,558 1,673,558
Convertible note payable 25,000 25,000
Convertible notes payable - related party, net of debt discount of $0 and $0, as of June 30, 2023 and December 31, 2022 173,192 173,192
Notes payable - related party - net of debt discount of $0 and $0 as of June 30, 2023 and December 31, 2022 106,850 106,850
Total Current Liabilities 4,197,372 4,110,276
Long Term Liabilities    
Convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022 485,825 480,155
Total Long-Term Liabilities 485,825 480,155
Total Liabilities 4,683,197 4,590,431
Commitments and Contingencies (Note 8)
Stockholders’ Deficit    
Preferred stock, $0.0001 par value, 50,000,000 shares authorized, none issued and outstanding as of June 30, 2023 and December 31, 2022
Common stock, $0.0001 par value: authorized 500,000,000, 21,674,000 and 21,674,000 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively 2,167 2,167
Additional paid-in capital 810,048 810,048
Accumulated deficit (5,157,560) (4,973,527)
Total Stockholders’ Deficit (4,345,345) (4,161,312)
Total Liabilities and Stockholders’ Deficit $ 337,852 $ 429,119
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Debt instrument, unamortized discount, current $ 0 $ 0
Notes payable - related party, debt discount - current 0 0
Convertible notes payable, debt discount - long term $ 14,175 $ 19,845
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000,000 50,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares, issued 21,674,000 21,674,000
Common stock shares outstanding 21,674,000 21,674,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenues - related party $ 67,500 $ 135,000
Costs and expenses        
General and administrative expenses 7,725 7,256 11,531 11,295
Professional fees 20,193 31,248 38,975 75,460
Salaries and wages 13,252 10,529 26,941 33,821
General and administrative expenses - related party 30,000 60,000
Total operating expenses 41,170 79,033 77,447 180,576
Loss from operations (41,170) (11,533) (77,447) (45,576)
Other income (expense)        
Unrealized gain (loss) on available for sale securities 1,329 (99,649) 6,644 (231,184)
Proceeds from sale of investment   287
Net loss allocated from equity method investees (41,102) (47,256)
Accreted interest income and interest income on note receivable 3,473 10,997
Interest expense (includes amortization of debt discount) (56,912) (58,616) (113,230) (116,657)
Total other (expense) (55,583) (195,894) (106,586) (383,813)
Net loss $ (96,753) $ (207,427) $ (184,033) $ (429,389)
Net Loss per share - basic $ (0.00) $ (0.01) $ (0.01) $ (0.02)
Net Loss per share - diluted $ (0.00) $ (0.01) $ (0.01) $ (0.02)
Weighted average number of shares - basic 21,674,000 21,674,000 21,674,000 21,674,000
Weighted average number of shares - diluted 21,674,000 21,674,000 21,674,000 21,674,000
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 2,167 $ 810,048 $ (4,205,176) $ (3,392,962)
Beginning balance, shares at Dec. 31, 2021 21,674,000      
Net loss (429,389) (429,389)
Ending balance, value at Jun. 30, 2022 $ 2,167 810,048 (4,634,565) (3,822,350)
Ending balance, shares at Jun. 30, 2022 21,674,000      
Beginning balance, value at Mar. 31, 2022 $ 2,167 810,048 (4,427,138) (3,614,923)
Beginning balance, shares at Mar. 31, 2022 21,674,000      
Net loss (207,427) (207,427)
Ending balance, value at Jun. 30, 2022 $ 2,167 810,048 (4,634,565) (3,822,350)
Ending balance, shares at Jun. 30, 2022 21,674,000      
Beginning balance, value at Dec. 31, 2022 $ 2,167 810,048 (4,973,527) (4,161,312)
Beginning balance, shares at Dec. 31, 2022 21,674,000      
Net loss (184,033) (184,033)
Ending balance, value at Jun. 30, 2023 $ 2,167 810,048 (5,157,560) (4,345,345)
Ending balance, shares at Jun. 30, 2023 21,674,000      
Beginning balance, value at Mar. 31, 2023 $ 2,167 810,048 (5,060,807) 4,248,592
Beginning balance, shares at Mar. 31, 2023 21,674,000      
Net loss (96,753) (96,753)
Ending balance, value at Jun. 30, 2023 $ 2,167 $ 810,048 $ (5,157,560) $ (4,345,345)
Ending balance, shares at Jun. 30, 2023 21,674,000      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Operating activities          
Net loss $ (96,753) $ (207,427) $ (184,033) $ (429,389)  
Adjustments to reconcile net loss to net cash used in operations          
Amortization of debt discount     5,670 9,098  
Accreted interest on note receivable     (3,308)  
Net loss from equity method investment     46,030  
Unrealized (gain) loss on available - for - sale securities     (6,644) 231,183  
Decrease (Increase) in          
Accounts receivable – related party     45,000 (22,500)  
Interest receivable     (7,690)  
Increase in          
Accounts payable and accrued expenses     87,096 115,561  
Accounts payable and accrued expenses - related party     60,000  
Accumulated losses on unconsolidated investees in excess of investment     1,226  
Net cash used in operating activities     (52,911) 211  
Net decrease in cash and cash equivalents     (52,911) 211  
Cash and cash equivalents - beginning of period     235,311 227,558 $ 227,558
Cash and cash equivalents - end of period $ 182,400 $ 227,769 182,400 227,769 $ 235,311
Supplemental disclosure of cash flow information          
Cash paid for interest      
Cash paid for income tax      
Supplemental disclosure of non-cash investing and financing activities          
Investment at fair value received from issuance of note receivable      
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Business Organization and Nature of Operations
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Business Organization and Nature of Operations

Note 1 – Business Organization and Nature of Operations

 

Balance Labs, Inc. (“Balance Labs” or the “Company”) was incorporated on June 5, 2014, under the laws of the State of Delaware. Balance Labs is a consulting firm that provides business development and consulting services to start up and development stage businesses. The Company seeks to offer services to help businesses in various industries improve and fine tune their business models, sales and marketing plans and internal operations as well as make introductions to professional services such as business plan writing, accounting firms and legal service providers.

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial position of Balance Labs as of June 30, 2023, and the unaudited consolidated results of its operations and cash flows for the six months ended June 30, 2023. The unaudited consolidated results of operations for the six months ended June 30, 2023, are not necessarily indicative of the operating results for the full year. It is recommended that these unaudited consolidated financial statements be read in conjunction with the audited financial statements and related disclosures of the Company for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on April 17, 2023.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Going Concern
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 2 – Going Concern

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company used $52,911 of cash in operating activities during the six months ended June 30, 2023, and currently has $182,400 in cash as of June 30, 2023. Additionally, at June 30, 2023, the Company had an accumulated deficit of $5,157,560 and a working capital deficit of $3,859,520.

 

There is substantial doubt about the Company to continue as a going concern for a period of twelve months from the date of these financial statements were made available. The Company without additional sources of debt or equity capital would potentially need to cease operations. Management plans to seek to raise additional capital within the next twelve months that is expected to sustain its operations for the next year. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing. In addition, the Company expects to begin a marketing campaign to market and sell its services. There can be no assurance that such a plan will be successful.

 

The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of 90 days or less to be cash equivalents. At June 30, 2023, and December 31, 2022, the Company has $2,000 in cash equivalents, respectively.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts by specific customer identification. If market conditions decline, actual collections may not meet expectations and may result in decreased cash flow and increased bad debt expense. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.

 

Revenue Recognition

 

The Company accounts for its revenues under FASB ASC 606, which is a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company considers revenue realized or realizable and earned when all the five following criteria are met: (1) Identify the Contract with a Customer, (2) Identify the Performance Obligations in the Contract, (3) Determine the Transaction Price, (4) Allocate the Transaction Price to the Performance Obligations in the Contract, and (5) Recognize Revenue When (or As) the Entity Satisfies a Performance Obligation.

 

The Company recognizes consulting income when the services are performed, and performance obligations are satisfied over time or point of time.

 

Income Taxes

 

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.

 

The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Management has evaluated and concluded that there are no material tax positions requiring recognition in the Company’s unaudited condensed consolidated financial statements as of June 30, 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s 2020, 2021, and 2022 tax returns remain open for audit for Federal and State taxing authorities.

 

The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statement of operations.

 

Marketable Securities

 

The Company accounts for marketable and available-for-sale securities under ASU 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income.

 

The Company accounts for its investment in EZFill Holdings, Inc. as available-for-sale securities pursuant to the S-1 Registration Statement declared effective on September 14, 2021, therefore, the unrealized gain (loss) on the available-for-sale securities during the six months ended June 30, 2023, and 2022 has been recorded in Other Income.

 

On December 2, 2020, the Company received 1,000,000 shares from EZFill Holdings, Inc, a related party, for past services, with each share valued at $1 each. At the time of acquiring these shares, EZFill Holdings, Inc. was not a publicly traded company.

 

On September 14, 2021, the S-1 Registration Statement for EZFill Holdings, Inc. was declared effective by the U.S. Securities and Exchange Commission. As a result of becoming a publicly traded company, our investment is now recorded at fair value as available-for-sale securities on June 30, 2023, with the gains and losses being recorded through other income on the consolidated statements of operations for the three then ended.

 

On November 18, 2020, the Company executed a two (2) year, third-party consulting agreement for various corporate services. The current service agreement has expired effective November 18, 2022. In connection with this agreement, and with the effectiveness of the Company’s Form S-1 registration statement, the Company was entitled to compensation as follows:

 

1,000,000 shares of common stock having a fair value of $1,000,000 ($1.00/share), each based on a recent cash price of the related party;

● a single payment of $200,000;

● during the first year of the agreement, $25,000 per month, with the 1st payment due 30 days after the completion of the Company’s IPO;

● during the second year of the agreement, $22,500 per month; and

● on each anniversary of the agreement, 500,000 shares of common stock.

 

At June 30, 2023, the Company owned 66,432 shares and the fair value of the investment in EZFill Holdings, Inc. was reported on the balance sheet as Investment at fair value - related party totaling $155,452 ($2.34/share). The Company recorded an adjustment of $6,644 for the six months ending June 30, 2023, as unrealized gain on securities. EZFill Holdings Inc. reported a 1 share for 8 share reverse stock split on April 26, 2023, which affected the total number of shares reported as of June 30, 2023.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Investments – Related Parties

 

When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein.

 

The Company holds one investment as of June 30, 2023, and one investment as of December 31, 2022.

 

Investments

 

On January 29, 2021, the Company received 20% ownership of Pharmacy No, 27, Ltd, a company based in Israel, as part of a Note Receivable from a third party (see Note 5). As of June 30, 2023, the investment has a fair value of $0, based upon the quoted closing trading price and it is recorded on our consolidated balance sheet using the equity method. During each six months ended June 30, 2023, the Company recorded $0 of unrealized loss from this investment.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2023, and December 31, 2022, the carrying value of marketable securities was $155,452 and $148,808, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).

 

Principles of Consolidation

 

The consolidated financial statements include the Company and its wholly owned corporate subsidiaries, Balance Labs LLC., from October 12, 2015, Balance AgroTech Co., from July 11, 2016, Advanced Auto Tech Co., from May 10, 2016, Balance Cannabis Co., from May 13, 2016, and Balance Medical Marijuana Co from December 22, 2015. All intercompany transactions are eliminated. The Company’s four subsidiaries, Balance AgroTech Co., Advanced AutoTech Co., Balance Cannabis Co., and Balance Medical Marijuana Co. are dormant.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Net Income (Loss) Per Common Share

 

Basic and diluted income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and warrants from convertible debentures outstanding during the periods. The effect of 0 and 40,000 warrants and 3,698,494 and 3,526,378 shares from convertible notes payable for the six months ended June 30, 2023, and 2022, respectively.

 

Stock-Based Compensation

 

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees.

 

The Company has computed the fair value of warrants granted using the Black-Scholes option pricing model. The expected term used for warrants is the contractual life. Since the Company’s stock has not been publicly traded for a sufficiently long period, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

 

Fair Value of Financial Instruments

 

The Company measures its financial assets and liabilities in accordance with GAAP. For certain of our financial instruments, including cash, accounts payable, and the short-term portion of long-term debt, the carrying amounts approximate fair value due to their short maturities.

 

We adopted accounting guidance for financial and non-financial assets and liabilities (ASC 820). This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2023.

  

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $155,452   $155,452   $     -   $     - 
Total Assets measured at fair value  $155,452   $155,452   $-   $- 

 

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2022.

 

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $148,808   $148,808   $      -   $      - 
Total Assets measured at fair value  $148,808   $148,808   $-   $- 

 

The Company accounts for its investment in EzFill Holdings, Inc. (“EzFill”) as available-for-sale securities. Since the investment is valued based on quoted market price using observable inputs.

 

Business Segments

 

The Company operates in one segment and therefore segment information is not presented.

 

Advertising, Marketing and Promotional Costs

 

Advertising, marketing, and promotional expenses are expensed as incurred and are included in selling, general and administrative expenses on the accompanying unaudited condensed consolidated statement of operations. For the six months ended June 30, 2023, and June 30, 2022, advertising, marketing, and promotion expense was $2,394 and $48, respectively.

 

Property and equipment

 

Property and equipment consist of furniture and office equipment and is stated at cost less accumulated depreciation. Depreciation is determined by using the straight-line method for furniture and office equipment, over the estimated useful lives of the related assets, generally three to five years.

 

Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the related assets.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Property and equipment as of June 30, 2023, and December 31, 2022 consisted of the following:

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
Website  $1,336   $1,336 
Computer equipment & Software   5,358    5,358 
Furniture   4,622    4,622 
Total   11,316    11,316 
Less Accumulated Depreciation   (11,316)   (11,316)
Property and Equipment, net  $-   $- 

 

Depreciation expense for the six months ended June 30, 2023, and 2022 totaled $0 and $0, respectively.

 

Recently Issued Accounting Pronouncements

 

The Company has evaluated all new accounting standards that are in effect and may impact its unaudited condensed consolidated financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders’ Equity

Note 4 – Stockholders’ Equity

 

Authorized Capital

 

The Company is authorized to issue 500,000,000 shares of common stock, $0.0001 par value, and 50,000,000 shares of preferred stock, $0.0001 par value.

 

Warrants

 

On October 3, 2019, the Company received $40,000 from The Sammy Farkas Foundation in exchange for a promissory note which bears 12% interest per annum and matured on October 10, 2020, or upon the Company raising $500,000 from outside investors, whichever occurs first. In conjunction with The Sammy Farkas Foundation agreement the Company issued warrants to purchase 40,000 shares of the Company’s common stock at an exercise price of $1.00 per share which expired on October 10, 2022. As of June 30, 2023, there are no warrants outstanding.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Note Receivable
6 Months Ended
Jun. 30, 2023
Receivables [Abstract]  
Note Receivable

Note 5 – Note Receivable

 

On September 30, 2021, Balance Labs Inc. made a loan to Four Acquisition, Ltd., an unrelated party in the principal amount of $22,000 which loan has an interest rate of 10% per annum and a maturity date of September 30, 2022. As of June 30, 2023, this receivable is fully reserved against. For the six months ended June 30, 2023 and 2022, the Company recorded $0 and $0, respectively, of interest income in relation to this note.

 

On January 29, 2021, Balance Labs Inc. made a loan to Four Acquisitions Ltd., an unrelated party in the principal amount of $119,000 which has an interest rate of 10% per annum and a maturity date of January 28, 2022. Additionally, in connection with the loan, the Company received a 20% interest in the recently acquired business and related assets of Four Acquisitions Ltd. Initially, this investment had a purchase price of $43,000, which was recorded as a discount from the note which will be amortized over the life of the note. The Company recorded an allowance of 100% against this receivable of $141,000 as of June 30, 2023.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 6 – Related Party Transactions

 

The Company’s CEO earned $10,000 per month through June 30, 2022. This agreement was terminated effective June 30, 2022. The following compensation was recorded within general and administrative expenses – related parties on the statements of operations: $0 and $30,000 for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and December 31, 2022, $0 and $30,000, respectively, of compensation was unpaid and was included in accounts payable – related party on the consolidated balance sheets.

 

On April 1, 2016, the Company received $500,000 from Newell Trading Group in exchange for a convertible debenture due April 2, 2017, bearing interest at 10% and convertible into common stock at $.25 per share unless the note is paid by the Company prior to the election of the holder to convert. The Company recognized a beneficial conversion feature expense of $500,000 that has been fully amortized. As of June 30, 2023 and December 31, 2022, accrued interest on the note is $350,000 and $300,000, respectively. On October 3, 2019, Newell Trading Group assigned its rights and interests in its $500,000 convertible debenture to the Sammy Farkas Foundation Inc., (the “Foundation”), a related party. The convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022 of $485,825 and $480,155, respectively was recorded under long term liability on the balance sheet.

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
16th Avenues Associates  $500,000   $500,000 
Debt discount   (14,175)   (19,845)
Convertible note payable – long term  $485,825   $480,155 

 

The Foundation then entered into an agreement with the Company to extend the maturity date of the convertible debenture to October 10, 2024 in exchange for 54,000 shares of the Company’s stock. The shares have a fair value of $56,700 which was recorded as a debt discount and was being amortized over the life of the extension. On November 11, 2019, The Sammy Farkas Foundation transferred all the rights and interests of the note to another party, 16th Avenue Associates, a non-related party company. The terms remain the same and the transfer has no effect on the financial statements. During the six months ended June 30, 2023 and December 31, 2022, the Company amortized $5,670 and $5,670, respectively of debt discount.

 

During 2016, 2017, and 2019 Balance Group LLC loaned an additional $66,850 to the Company. The notes are in default and have an accrued interest balance of $29,481. The note balance of $66,850 is included in the note payable – related party in current liability as of June 30, 2023 and December 31, 2022.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

On October 3, 2019, the Company received $40,000 from The Foundation in exchange for a promissory note which bears 12% interest per annum and matured on October 10, 2020 or upon the Company raising $500,000 from outside investors, whichever occurs first. The promissory note is currently in default, and as of June 30, 2023, accrued interest on the note is $20,818. The note balance of $40,000 is included in the note payable – related party in current liability as of June 30, 2023 and December 31, 2022.

 

The promissory note comes with a warrant to purchase 40,000 shares of the Company’s stock with an exercise price of $1.00 per share and expired on October 10, 2022. The warrants had a relative fair value of $8,283, which was recorded as a debt discount and fully amortized.

  

   June 30,
2023
(unaudited)
   December 31,
2022
 
Balance Group LLC  $66,850   $66,850 
The Foundation   40,000    40,000 
Note Payable – related party  $106,850   $106,850 

 

On June 27, 2021, the Company received $50,000 from the CEO in exchange for a convertible promissory note with a face value of $53,192 which bears 12% interest per annum and matures on June 27, 2022, or upon the Company raising $250,000 from investors, whichever occurs first. The note balance of $53,192 is included in the convertible notes payable - related party, net of debt discount of $0 and $3,428, as of June 30, 2023, and December 31, 2022, respectively. The difference between the amount received and the face value of $3,192 was recorded as a discount and is being amortized over the life of the note. Additionally, the note comes with a beneficial conversion feature of $3,799 which was also recorded as a component of equity in 2021. As of June 30, 2023, the Company has accrued interest of $12,801 and is recorded in the accrued expenses on the balance sheet.

 

On September 30, 2016, Balance Group LLC loaned $120,000 as a convertible note payable to the Company at an interest rate of 10%, due on October 1, 2017. In addition, the Company issued 600,000 warrants at an exercise price of $1 which expired on September 30, 2021 (See Note 9). The note is currently in default and is currently recorded under convertible payable – related party in current liabilities in the balance sheet. The accrued interest balance of $81,008 is recorded in the accrued expenses on the balance sheet as of June 30, 2023.

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
Balance Group LLC  $120,000   $120,000 
Note Payable from CEO   53,192    53,192 
Convertible note payable- related party  $173,192   $173,192 

 

On July 9, 2021, Krypto Ventures, Inc. formerly known as KryptoBank Co. issued an unsecured promissory note in the amount of $25,000 to Lyons Capital LLC, a significant shareholder of Krypto Ventures, Inc. The note carries an interest rate of 12% and is due on the earlier of July 8, 2022, or the date on which Krypto Ventures, Inc. raises at least $200,000. As of July 29, 2021, the Company has accrued interest of $164. The note and accrued interest were deconsolidated as part of deconsolidation of Krypto Ventures, Inc.

 

On June 29, 2021, Balance Labs Inc. made a loan to Krypto Ventures, Inc, formerly known as KryptoBank Co., a related party in the principal amount of $25,000 which loan has an interest rate of 12% per annum and a maturity date of June 28, 2022.

 

As of June 30, 2023 and December 31, 2022, the CEO and companies controlled by the CEO have loaned the Company a total of $1,673,558 in addition to the convertible notes discussed above. The loans carry an interest rate of 8% and mature one year and one day from the date of the loan. These loans of $1,673,558 and the accrued interest on these loans of $418,111 are in default as of June 30, 2023. These loans of $1,673,558 are in default and are reported under short -term advances from related party on the balance sheet as of June 30, 2023 and December 31, 2022.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible Notes and Notes Payable
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Convertible Notes and Notes Payable

Note 7 – Convertible Notes and Notes Payable

 

Notes Payable

 

For all information regarding the related party note payable see note 6.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Convertible Notes Payable

 

On April 1, 2016, the Company received $500,000 from Newell Trading Group in exchange for a convertible debenture due April 2, 2017, bearing interest at 10% and convertible into common stock at $.25 per share unless the note is paid by the Company prior to the election of the holder to convert. The Company recognized a beneficial conversion feature expense of $500,000 that has been fully amortized. As of December 31, 2021, accrued interest on the note is $287,671. On October 3, 2019, Newell Trading Group assigned its rights and interests in its $500,000 convertible debenture to the Sammy Farkas Foundation Inc., (the “Foundation”), a related party. The Foundation then entered into an agreement with the Company to extend the maturity date of the convertible debenture to October 10, 2024 in exchange for 54,000 shares of the Company’s stock. The shares have a fair value of $56,700 which was recorded as a debt discount and amortized over the life of the extension. On November 11, 2019, The Sammy Farkas Foundation transferred all the rights and interests of the note to another party, 16th Avenue Associates. The terms remain the same and the transfer has no effect on the financial statements. The convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022 was $485,825 and $480,155, respectively, and was recorded under long term liability on the balance sheet.

  

   June 30,
2023
(unaudited)
   December 31,
2022
 
Newell Trading Group  $500,000   $500,000 
Debt discount   (14,175)   (19,845)
Convertible note payable – long term  $485,825   $480,155 

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 8 – Commitments and Contingencies

 

Litigation, Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s condensed consolidated financial position or results of operations.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of 90 days or less to be cash equivalents. At June 30, 2023, and December 31, 2022, the Company has $2,000 in cash equivalents, respectively.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.

 

Accounts Receivable

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts by specific customer identification. If market conditions decline, actual collections may not meet expectations and may result in decreased cash flow and increased bad debt expense. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.

 

Revenue Recognition

Revenue Recognition

 

The Company accounts for its revenues under FASB ASC 606, which is a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company considers revenue realized or realizable and earned when all the five following criteria are met: (1) Identify the Contract with a Customer, (2) Identify the Performance Obligations in the Contract, (3) Determine the Transaction Price, (4) Allocate the Transaction Price to the Performance Obligations in the Contract, and (5) Recognize Revenue When (or As) the Entity Satisfies a Performance Obligation.

 

The Company recognizes consulting income when the services are performed, and performance obligations are satisfied over time or point of time.

 

Income Taxes

Income Taxes

 

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.

 

The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Management has evaluated and concluded that there are no material tax positions requiring recognition in the Company’s unaudited condensed consolidated financial statements as of June 30, 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s 2020, 2021, and 2022 tax returns remain open for audit for Federal and State taxing authorities.

 

The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statement of operations.

 

Marketable Securities

Marketable Securities

 

The Company accounts for marketable and available-for-sale securities under ASU 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income.

 

The Company accounts for its investment in EZFill Holdings, Inc. as available-for-sale securities pursuant to the S-1 Registration Statement declared effective on September 14, 2021, therefore, the unrealized gain (loss) on the available-for-sale securities during the six months ended June 30, 2023, and 2022 has been recorded in Other Income.

 

On December 2, 2020, the Company received 1,000,000 shares from EZFill Holdings, Inc, a related party, for past services, with each share valued at $1 each. At the time of acquiring these shares, EZFill Holdings, Inc. was not a publicly traded company.

 

On September 14, 2021, the S-1 Registration Statement for EZFill Holdings, Inc. was declared effective by the U.S. Securities and Exchange Commission. As a result of becoming a publicly traded company, our investment is now recorded at fair value as available-for-sale securities on June 30, 2023, with the gains and losses being recorded through other income on the consolidated statements of operations for the three then ended.

 

On November 18, 2020, the Company executed a two (2) year, third-party consulting agreement for various corporate services. The current service agreement has expired effective November 18, 2022. In connection with this agreement, and with the effectiveness of the Company’s Form S-1 registration statement, the Company was entitled to compensation as follows:

 

1,000,000 shares of common stock having a fair value of $1,000,000 ($1.00/share), each based on a recent cash price of the related party;

● a single payment of $200,000;

● during the first year of the agreement, $25,000 per month, with the 1st payment due 30 days after the completion of the Company’s IPO;

● during the second year of the agreement, $22,500 per month; and

● on each anniversary of the agreement, 500,000 shares of common stock.

 

At June 30, 2023, the Company owned 66,432 shares and the fair value of the investment in EZFill Holdings, Inc. was reported on the balance sheet as Investment at fair value - related party totaling $155,452 ($2.34/share). The Company recorded an adjustment of $6,644 for the six months ending June 30, 2023, as unrealized gain on securities. EZFill Holdings Inc. reported a 1 share for 8 share reverse stock split on April 26, 2023, which affected the total number of shares reported as of June 30, 2023.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Investments – Related Parties

Investments – Related Parties

 

When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein.

 

The Company holds one investment as of June 30, 2023, and one investment as of December 31, 2022.

 

Investments

Investments

 

On January 29, 2021, the Company received 20% ownership of Pharmacy No, 27, Ltd, a company based in Israel, as part of a Note Receivable from a third party (see Note 5). As of June 30, 2023, the investment has a fair value of $0, based upon the quoted closing trading price and it is recorded on our consolidated balance sheet using the equity method. During each six months ended June 30, 2023, the Company recorded $0 of unrealized loss from this investment.

 

Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2023, and December 31, 2022, the carrying value of marketable securities was $155,452 and $148,808, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).

 

Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the Company and its wholly owned corporate subsidiaries, Balance Labs LLC., from October 12, 2015, Balance AgroTech Co., from July 11, 2016, Advanced Auto Tech Co., from May 10, 2016, Balance Cannabis Co., from May 13, 2016, and Balance Medical Marijuana Co from December 22, 2015. All intercompany transactions are eliminated. The Company’s four subsidiaries, Balance AgroTech Co., Advanced AutoTech Co., Balance Cannabis Co., and Balance Medical Marijuana Co. are dormant.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Net Income (Loss) Per Common Share

Net Income (Loss) Per Common Share

 

Basic and diluted income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and warrants from convertible debentures outstanding during the periods. The effect of 0 and 40,000 warrants and 3,698,494 and 3,526,378 shares from convertible notes payable for the six months ended June 30, 2023, and 2022, respectively.

 

Stock-Based Compensation

Stock-Based Compensation

 

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees.

 

The Company has computed the fair value of warrants granted using the Black-Scholes option pricing model. The expected term used for warrants is the contractual life. Since the Company’s stock has not been publicly traded for a sufficiently long period, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company measures its financial assets and liabilities in accordance with GAAP. For certain of our financial instruments, including cash, accounts payable, and the short-term portion of long-term debt, the carrying amounts approximate fair value due to their short maturities.

 

We adopted accounting guidance for financial and non-financial assets and liabilities (ASC 820). This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2023.

  

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $155,452   $155,452   $     -   $     - 
Total Assets measured at fair value  $155,452   $155,452   $-   $- 

 

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2022.

 

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $148,808   $148,808   $      -   $      - 
Total Assets measured at fair value  $148,808   $148,808   $-   $- 

 

The Company accounts for its investment in EzFill Holdings, Inc. (“EzFill”) as available-for-sale securities. Since the investment is valued based on quoted market price using observable inputs.

 

Business Segments

Business Segments

 

The Company operates in one segment and therefore segment information is not presented.

 

Advertising, Marketing and Promotional Costs

Advertising, Marketing and Promotional Costs

 

Advertising, marketing, and promotional expenses are expensed as incurred and are included in selling, general and administrative expenses on the accompanying unaudited condensed consolidated statement of operations. For the six months ended June 30, 2023, and June 30, 2022, advertising, marketing, and promotion expense was $2,394 and $48, respectively.

 

Property and equipment

Property and equipment

 

Property and equipment consist of furniture and office equipment and is stated at cost less accumulated depreciation. Depreciation is determined by using the straight-line method for furniture and office equipment, over the estimated useful lives of the related assets, generally three to five years.

 

Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the related assets.

 

 

BALANCE LABS, INC.

Condensed Notes to Consolidated Financial Statements

As of June 30, 2023

(Unaudited)

 

Property and equipment as of June 30, 2023, and December 31, 2022 consisted of the following:

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
Website  $1,336   $1,336 
Computer equipment & Software   5,358    5,358 
Furniture   4,622    4,622 
Total   11,316    11,316 
Less Accumulated Depreciation   (11,316)   (11,316)
Property and Equipment, net  $-   $- 

 

Depreciation expense for the six months ended June 30, 2023, and 2022 totaled $0 and $0, respectively.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

The Company has evaluated all new accounting standards that are in effect and may impact its unaudited condensed consolidated financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Schedule of Fair Value of Assets on Recurring Basis

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2023.

  

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $155,452   $155,452   $     -   $     - 
Total Assets measured at fair value  $155,452   $155,452   $-   $- 

 

The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2022.

 

   Total   (Level 1)   (Level 2)   (Level 3) 
Fair-value – equity securities  $148,808   $148,808   $      -   $      - 
Total Assets measured at fair value  $148,808   $148,808   $-   $- 
Schedule of Property and Equipment

Property and equipment as of June 30, 2023, and December 31, 2022 consisted of the following:

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
Website  $1,336   $1,336 
Computer equipment & Software   5,358    5,358 
Furniture   4,622    4,622 
Total   11,316    11,316 
Less Accumulated Depreciation   (11,316)   (11,316)
Property and Equipment, net  $-   $- 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions (Tables)
6 Months Ended
Jun. 30, 2023
Related Party Transaction [Line Items]  
Schedule of Convertible Note Payable - Long Term

  

   June 30,
2023
(unaudited)
   December 31,
2022
 
Newell Trading Group  $500,000   $500,000 
Debt discount   (14,175)   (19,845)
Convertible note payable – long term  $485,825   $480,155 
Schedule of Note Payable - Related Party

  

   June 30,
2023
(unaudited)
   December 31,
2022
 
Balance Group LLC  $66,850   $66,850 
The Foundation   40,000    40,000 
Note Payable – related party  $106,850   $106,850 
Schedule of Convertible Note Payable - Related Party

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
Balance Group LLC  $120,000   $120,000 
Note Payable from CEO   53,192    53,192 
Convertible note payable- related party  $173,192   $173,192 
Newell Trading Group [Member]  
Related Party Transaction [Line Items]  
Schedule of Convertible Note Payable - Long Term

 

   June 30,
2023
(unaudited)
   December 31,
2022
 
16th Avenues Associates  $500,000   $500,000 
Debt discount   (14,175)   (19,845)
Convertible note payable – long term  $485,825   $480,155 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible Notes and Notes Payable (Tables)
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Convertible Note Payable - Long Term

  

   June 30,
2023
(unaudited)
   December 31,
2022
 
Newell Trading Group  $500,000   $500,000 
Debt discount   (14,175)   (19,845)
Convertible note payable – long term  $485,825   $480,155 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Going Concern (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Net cash provided (used in) operating activities $ 52,911 $ (211)  
Cash 182,400   $ 235,311
Accumulated deficit 5,157,560   $ 4,973,527
Working capital $ 3,859,520    
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Fair Value of Assets on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair-value - equity securities $ 155,452 $ 148,808
Total Assets measured at fair value 155,452 148,808
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair-value - equity securities 155,452 148,808
Total Assets measured at fair value 155,452 148,808
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair-value - equity securities
Total Assets measured at fair value
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair-value - equity securities
Total Assets measured at fair value
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Property and Equipment (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total $ 11,316 $ 11,316
Less Accumulated Depreciation (11,316) (11,316)
Property and Equipment, net
Website [Member]    
Property, Plant and Equipment [Line Items]    
Total 1,336 1,336
Computer Equipment & Software [Member]    
Property, Plant and Equipment [Line Items]    
Total 5,358 5,358
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Total $ 4,622 $ 4,622
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 6 Months Ended
Nov. 18, 2022
USD ($)
$ / shares
shares
Dec. 02, 2020
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
integer
$ / shares
shares
Jun. 30, 2022
USD ($)
shares
Dec. 31, 2022
USD ($)
Jan. 29, 2021
Property, Plant and Equipment [Line Items]                
Cash equivalents     $ 2,000   $ 2,000   $ 2,000  
Issuance of shares | shares 1,000,000              
Issuance of value $ 1,000,000              
Shares issued price, per share | $ / shares $ 1.00   $ 2.34   $ 2.34      
Salaries and wages     $ 13,252 $ 10,529 $ 26,941 $ 33,821    
Fair value of investment cost | shares     66,432   66,432      
Fair value of investment cost     $ 155,452   $ 155,452      
Unrealized loss on securities         $ 6,644      
Reverse stock split description         1 share for 8 share reverse stock split      
Investments     0   $ 0      
Marketable securities     $ 155,452   $ 155,452   $ 148,808  
Number of operating segment | integer         1      
Advertising, marketing and promotion expense         $ 2,394 48    
Depreciation            
Minimum [Member]                
Property, Plant and Equipment [Line Items]                
Property, plant and equipment, estimated useful life     3 years   3 years      
Maximum [Member]                
Property, Plant and Equipment [Line Items]                
Property, plant and equipment, estimated useful life     5 years   5 years      
Convertible Notes Payable [Member]                
Property, Plant and Equipment [Line Items]                
Antidilutive securities excluded from earnings per share amount | shares         3,698,494 3,526,378    
Warrant [Member]                
Property, Plant and Equipment [Line Items]                
Antidilutive securities excluded from earnings per share amount | shares         0 40,000    
Pharmacy No 27 Ltd [Member]                
Property, Plant and Equipment [Line Items]                
Ownership percentage               20.00%
Unrealized loss on investments     $ 0   $ 0      
Each Anniversary [Member]                
Property, Plant and Equipment [Line Items]                
Salaries and wages $ 500,000              
IPO [Member]                
Property, Plant and Equipment [Line Items]                
Salaries and wages 200,000              
IPO [Member] | First Year [Member] | Monthly [Member]                
Property, Plant and Equipment [Line Items]                
Salaries and wages 25,000              
IPO [Member] | Second Year [Member] | Monthly [Member]                
Property, Plant and Equipment [Line Items]                
Salaries and wages $ 22,500              
EZFill Holdings, Inc, [Member]                
Property, Plant and Equipment [Line Items]                
Issuance of shares | shares   1,000,000            
Share price | $ / shares   $ 1            
Related Party [Member]                
Property, Plant and Equipment [Line Items]                
Equity method investment percentage, description         When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein      
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Details Narrative) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Oct. 03, 2019
Defined Benefit Plan Disclosure [Line Items]      
Common stock, shares authorized 500,000,000 500,000,000  
Common stock, par value $ 0.0001 $ 0.0001  
Preferred stock, shares authorized 50,000,000 50,000,000  
Preferred stock, par value $ 0.0001 $ 0.0001  
Debt instrument, face amount $ 500,000 $ 500,000  
Sammy Farkas Foundation Inc. [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Debt instrument, face amount     $ 40,000
Interest rate of related party loan     12.00%
Due to related parties     $ 500,000
Warrants issued to purchase of common stock shares     40,000
Warrants exercise price per share     $ 1.00
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Note Receivable (Details Narrative) - USD ($)
6 Months Ended
Sep. 30, 2021
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Jan. 29, 2021
Restructuring Cost and Reserve [Line Items]          
Debt instrument face amount   $ 500,000   $ 500,000  
Notes receivable unamortized allowance current, percentage   100.00%      
Notes receivable unamortized allowance current   $ 141,000      
Four Acquisitions Ltd [Member]          
Restructuring Cost and Reserve [Line Items]          
Debt instrument face amount $ 22,000       $ 119,000
Debt instrument interest rate stated percentage 10.00%       10.00%
Debt maturity date Sep. 30, 2022        
Interest income related party   $ 0 $ 0    
Equity interest acquire percentage         20.00%
Investments fair value disclosure         $ 43,000
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Convertible Note Payable - Long Term (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Related Party Transactions [Abstract]    
Convertible note payable – long term, gross $ 500,000 $ 500,000
Debt discount (14,175) (19,845)
Convertible note payable – long term $ 485,825 $ 480,155
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Note Payable - Related Party (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]    
Note Payable – related party $ 106,850 $ 106,850
Balance Group LLC [Member]    
Related Party Transaction [Line Items]    
Note Payable – related party 66,850 66,850
Foundation [Member]    
Related Party Transaction [Line Items]    
Note Payable – related party $ 40,000 $ 40,000
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Convertible Note Payable - Related Party (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]    
Convertible note payable- related party $ 173,192 $ 173,192
Chief Executive Officer [Member]    
Related Party Transaction [Line Items]    
Convertible note payable- related party 53,192 53,192
Balance Group LLC [Member]    
Related Party Transaction [Line Items]    
Convertible note payable- related party $ 120,000 $ 120,000
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Jun. 29, 2021
Jun. 27, 2021
Oct. 03, 2019
Apr. 01, 2016
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jul. 29, 2021
Jul. 09, 2021
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Related Party Transaction [Line Items]                              
Debt instrument unamortized discount         $ 14,175   $ 19,845                
Amortization of debt discount         5,670 $ 9,098                  
Convertible notes payable         25,000   25,000                
Debt instrument face amount         500,000   500,000                
Short-term advances from related party         1,673,558   1,673,558                
Balance Group LLC [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument interest rate stated percentage                             10.00%
Interest payable current and noncurrent         29,481                    
Convertible notes payable                       $ 66,850 $ 66,850 $ 66,850 $ 120,000
Convertible notes payable         66,850   66,850                
Warrants exercise price per share                 $ 1            
Number of warrants issued to related party                 600,000            
Accrued interest         81,008                    
Sammy Farkas Foundation Inc. [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument interest rate stated percentage     12.00%                        
Interest payable current and noncurrent         20,818                    
Debt instrument, increase (decrease), net     $ 500,000                        
Convertible notes payable         40,000   40,000                
Debt instrument face amount     40,000                        
Due to related parties     $ 500,000                        
Warrants exercise price per share     $ 1.00                        
Lyons Capital LLC [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument interest rate stated percentage 12.00%                   12.00%        
Unsecured debt                     $ 25,000        
Krypto Ventures Inc [Member]                              
Related Party Transaction [Line Items]                              
Interest payable current and noncurrent                   $ 164          
Debt instrument face amount                     $ 200,000        
Debt instrument maturity date Jun. 28, 2022                            
Financing Receivable, after Allowance for Credit Loss $ 25,000                            
Convertible Debenture [Member]                              
Related Party Transaction [Line Items]                              
Proceeds from convertible debt       $ 500,000                      
Debt instrument interest rate stated percentage       10.00%                      
Debt instrument convertible conversion price       $ 0.25                      
Debt instrument, convertible, beneficial conversion       $ 500,000                      
Interest payable current and noncurrent         350,000   300,000 $ 287,671              
Debt instrument discount         14,175   19,845                
Long term debt         485,825   480,155                
Debt instrument maturity rate     Oct. 10, 2024                        
Number of shares exchange     54,000                        
Debt instrument unamortized discount     $ 56,700                        
Amortization of debt discount         5,670   5,670                
Debt instrument maturity date       Apr. 02, 2017                      
Convertible Debenture [Member] | Related Party [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument discount         14,175   19,845                
Promissory Note [Member] | Warrant [Member]                              
Related Party Transaction [Line Items]                              
Class of warrants     40,000                        
Warrants exercise price per share     $ 1.00                        
Fair value of warrants         8,283                    
Chief Executive Officer [Member]                              
Related Party Transaction [Line Items]                              
Officers compensation         10,000                    
General and administrative expenses - related party         0 $ 30,000                  
Accounts payable related party         0   30,000                
Debt instrument interest rate stated percentage   12.00%                          
Debt instrument, convertible, beneficial conversion   $ 3,799                          
Interest payable current and noncurrent         12,801                    
Debt instrument, increase (decrease), net   250,000                          
Debt instrument discount         0   $ 3,428                
Amortization of debt discount   3,192                          
Convertible notes payable   53,192                          
Debt instrument face amount   53,192                          
Due to related parties   $ 50,000                          
Debt instrument maturity date   Jun. 27, 2022                          
Chief Executive Officer and Company's Controlled by Chief Executive Officer [Member] | Convertible Notes Payable [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument interest rate stated percentage             8.00%                
Interest payable current and noncurrent         418,111                    
Due to related parties         $ 1,673,558   $ 1,673,558                
Short-term advances from related party             $ 1,673,558                
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible Notes and Notes Payable (Details Narrative) - USD ($)
Oct. 03, 2019
Apr. 01, 2016
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]          
Debt Instrument, Unamortized Discount, Noncurrent     $ 14,175 $ 19,845  
Sammy Farkas Foundation Inc. [Member]          
Short-Term Debt [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage 12.00%        
Interest Payable     20,818    
Debt Instrument, Increase (Decrease), Net $ 500,000        
Convertible Debenture [Member]          
Short-Term Debt [Line Items]          
Proceeds from Convertible Debt   $ 500,000      
Debt Instrument, Maturity Date   Apr. 02, 2017      
Debt Instrument, Interest Rate, Stated Percentage   10.00%      
Debt Instrument, Convertible, Conversion Price   $ 0.25      
Debt Instrument, Convertible, Beneficial Conversion Feature   $ 500,000      
Interest Payable     350,000 300,000 $ 287,671
Debt instrument, extended maturity date Oct. 10, 2024        
Number of shares exchange 54,000        
Debt Instrument, Unamortized Discount, Noncurrent $ 56,700        
Debt Instrument, Unamortized Discount     14,175 19,845  
Debt Instrument, Unamortized Discount (Premium), Net     $ 485,825 $ 480,155  
XML 40 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001632121 2023-01-01 2023-06-30 0001632121 2023-08-11 0001632121 2023-06-30 0001632121 2022-12-31 0001632121 2023-04-01 2023-06-30 0001632121 2022-04-01 2022-06-30 0001632121 2022-01-01 2022-06-30 0001632121 us-gaap:CommonStockMember 2023-03-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001632121 us-gaap:RetainedEarningsMember 2023-03-31 0001632121 2023-03-31 0001632121 us-gaap:CommonStockMember 2022-12-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001632121 us-gaap:RetainedEarningsMember 2022-12-31 0001632121 us-gaap:CommonStockMember 2022-03-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001632121 us-gaap:RetainedEarningsMember 2022-03-31 0001632121 2022-03-31 0001632121 us-gaap:CommonStockMember 2021-12-31 0001632121 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001632121 us-gaap:RetainedEarningsMember 2021-12-31 0001632121 2021-12-31 0001632121 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001632121 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001632121 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001632121 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001632121 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001632121 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001632121 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001632121 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001632121 us-gaap:CommonStockMember 2023-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001632121 us-gaap:RetainedEarningsMember 2023-06-30 0001632121 us-gaap:CommonStockMember 2022-06-30 0001632121 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001632121 us-gaap:RetainedEarningsMember 2022-06-30 0001632121 2022-06-30 0001632121 BLNC:EZFillHoldingsIncMember 2020-12-02 2020-12-02 0001632121 BLNC:EZFillHoldingsIncMember 2020-12-02 0001632121 2022-11-17 2022-11-18 0001632121 2022-11-18 0001632121 us-gaap:IPOMember 2022-11-17 2022-11-18 0001632121 BLNC:FirstYearMember BLNC:MonthlyMember us-gaap:IPOMember 2022-11-17 2022-11-18 0001632121 BLNC:SecondYearMember BLNC:MonthlyMember us-gaap:IPOMember 2022-11-17 2022-11-18 0001632121 BLNC:EachAnniversaryMember 2022-11-17 2022-11-18 0001632121 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001632121 BLNC:PharmacyNo27LtdMember 2021-01-29 0001632121 BLNC:PharmacyNo27LtdMember 2023-06-30 0001632121 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001632121 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001632121 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-06-30 0001632121 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-06-30 0001632121 srt:MinimumMember 2023-06-30 0001632121 srt:MaximumMember 2023-06-30 0001632121 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001632121 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001632121 BLNC:WebsiteMember 2023-06-30 0001632121 BLNC:WebsiteMember 2022-12-31 0001632121 BLNC:ComputerEquipmentAndSoftwareMember 2023-06-30 0001632121 BLNC:ComputerEquipmentAndSoftwareMember 2022-12-31 0001632121 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001632121 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001632121 BLNC:SammyFarkasFoundationIncMember 2019-10-03 0001632121 BLNC:FourAcquisitionsLtdMember 2021-09-30 0001632121 BLNC:FourAcquisitionsLtdMember 2021-09-29 2021-09-30 0001632121 BLNC:FourAcquisitionsLtdMember 2023-01-01 2023-06-30 0001632121 BLNC:FourAcquisitionsLtdMember 2022-01-01 2022-06-30 0001632121 BLNC:FourAcquisitionsLtdMember 2021-01-29 0001632121 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2023-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2022-12-31 0001632121 BLNC:ConvertibleDebentureMember 2016-03-28 2016-04-01 0001632121 BLNC:ConvertibleDebentureMember 2016-04-01 0001632121 BLNC:ConvertibleDebentureMember 2023-06-30 0001632121 BLNC:ConvertibleDebentureMember 2022-12-31 0001632121 BLNC:SammyFarkasFoundationIncMember 2019-10-02 2019-10-03 0001632121 BLNC:ConvertibleDebentureMember us-gaap:RelatedPartyMember 2023-06-30 0001632121 BLNC:ConvertibleDebentureMember us-gaap:RelatedPartyMember 2022-12-31 0001632121 BLNC:ConvertibleDebentureMember 2019-10-02 2019-10-03 0001632121 BLNC:ConvertibleDebentureMember 2019-10-03 0001632121 BLNC:ConvertibleDebentureMember 2023-01-01 2023-06-30 0001632121 BLNC:ConvertibleDebentureMember 2022-01-01 2022-12-31 0001632121 BLNC:BalanceGroupLLCMember 2016-12-31 0001632121 BLNC:BalanceGroupLLCMember 2017-12-31 0001632121 BLNC:BalanceGroupLLCMember 2019-12-31 0001632121 BLNC:BalanceGroupLLCMember 2023-06-30 0001632121 BLNC:BalanceGroupLLCMember 2022-12-31 0001632121 BLNC:SammyFarkasFoundationIncMember 2023-06-30 0001632121 BLNC:SammyFarkasFoundationIncMember 2022-12-31 0001632121 BLNC:PromissoryNoteMember us-gaap:WarrantMember 2019-10-03 0001632121 BLNC:PromissoryNoteMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001632121 srt:ChiefExecutiveOfficerMember 2021-06-27 0001632121 srt:ChiefExecutiveOfficerMember 2021-06-26 2021-06-27 0001632121 BLNC:BalanceGroupLLCMember 2016-09-30 0001632121 BLNC:BalanceGroupLLCMember 2021-09-30 0001632121 BLNC:BalanceGroupLLCMember 2023-01-01 2023-06-30 0001632121 BLNC:LyonsCapitalLLCMember 2021-07-09 0001632121 BLNC:KryptoVenturesIncMember 2021-07-09 0001632121 BLNC:KryptoVenturesIncMember 2021-07-29 0001632121 BLNC:KryptoVenturesIncMember 2021-06-29 0001632121 BLNC:LyonsCapitalLLCMember 2021-06-29 0001632121 BLNC:KryptoVenturesIncMember 2021-06-28 2021-06-29 0001632121 BLNC:ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001632121 BLNC:ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0001632121 BLNC:NewellTradingGroupMember 2023-01-01 2023-06-30 0001632121 BLNC:BalanceGroupLLCMember 2023-06-30 0001632121 BLNC:BalanceGroupLLCMember 2022-12-31 0001632121 BLNC:FoundationMember 2023-06-30 0001632121 BLNC:FoundationMember 2022-12-31 0001632121 BLNC:ConvertibleDebentureMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure BLNC:Segment utr:sqft BLNC:integer 0001632121 false Q2 --12-31 P3Y 2017-04-02 10-Q true 2023-06-30 2023 false 333-202959 BALANCE LABS, INC. DE 47-1146785 407 Lincoln Road Suite 701 Miami Beach FL 33139 (305) 907-7600 No Yes Non-accelerated Filer true false false 21674000 182400 235311 45000 155452 148808 337852 429119 337852 429119 1307113 1220017 911659 911659 1673558 1673558 25000 25000 0 0 173192 173192 0 0 106850 106850 4197372 4110276 14175 19845 485825 480155 485825 480155 4683197 4590431 0.0001 0.0001 50000000 50000000 0 0 0 0 0.0001 0.0001 500000000 500000000 21674000 21674000 21674000 21674000 2167 2167 810048 810048 -5157560 -4973527 -4345345 -4161312 337852 429119 67500 135000 7725 7256 11531 11295 20193 31248 38975 75460 13252 10529 26941 33821 30000 60000 41170 79033 77447 180576 -41170 -11533 -77447 -45576 1329 -99649 6644 -231184 287 -41102 -47256 3473 10997 56912 58616 113230 116657 -55583 -195894 -106586 -383813 -96753 -207427 -184033 -429389 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 21674000 21674000 21674000 21674000 21674000 21674000 21674000 21674000 21674000 2167 810048 -5060807 4248592 -96753 -96753 21674000 2167 810048 -5157560 -4345345 21674000 2167 810048 -4973527 -4161312 -184033 -184033 21674000 2167 810048 -5157560 -4345345 21674000 2167 810048 -4427138 -3614923 -207427 -207427 21674000 2167 810048 -4634565 -3822350 21674000 2167 810048 -4205176 -3392962 -429389 -429389 21674000 2167 810048 -4634565 -3822350 -184033 -429389 5670 9098 3308 46030 6644 -231183 -45000 22500 7690 87096 115561 60000 1226 -52911 211 -52911 211 235311 227558 182400 227769 <p id="xdx_803_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zsPFyOIiL9W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_822_zKaeTsk5Izl5">Business Organization and Nature of Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Labs, Inc. (“Balance Labs” or the “Company”) was incorporated on June 5, 2014, under the laws of the State of Delaware. Balance Labs is a consulting firm that provides business development and consulting services to start up and development stage businesses. The Company seeks to offer services to help businesses in various industries improve and fine tune their business models, sales and marketing plans and internal operations as well as make introductions to professional services such as business plan writing, accounting firms and legal service providers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial position of Balance Labs as of June 30, 2023, and the unaudited consolidated results of its operations and cash flows for the six months ended June 30, 2023. The unaudited consolidated results of operations for the six months ended June 30, 2023, are not necessarily indicative of the operating results for the full year. It is recommended that these unaudited consolidated financial statements be read in conjunction with the audited financial statements and related disclosures of the Company for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on April 17, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zS6GgECNH5a8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_82F_z1G1iFqNhsLg">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company used $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20230630_zURrYfYTzP0j" title="Net cash provided (used in) operating activities">52,911</span> of cash in operating activities during the six months ended June 30, 2023, and currently has $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230630_zB8mghrycldf" title="Cash">182,400</span></span> in cash as of June 30, 2023. Additionally, at June 30, 2023, the Company had an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230630_z3GPysilGLd8" title="Accumulated deficit">5,157,560</span> and a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iNI_di_c20230630_znzRJjQDeAZ5" title="Working capital">3,859,520</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial doubt about the Company to continue as a going concern for a period of twelve months from the date of these financial statements were made available. The Company without additional sources of debt or equity capital would potentially need to cease operations. Management plans to seek to raise additional capital within the next twelve months that is expected to sustain its operations for the next year. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing. In addition, the Company expects to begin a marketing campaign to market and sell its services. There can be no assurance that such a plan will be successful.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -52911 182400 -5157560 -3859520 <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zQORZcp0LyZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_822_zIxsAWFb4SAd">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zK1cx5CDyC29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_861_zennhR2udxrb">Cash and Cash Equivalents</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of 90 days or less to be cash equivalents. At June 30, 2023, and December 31, 2022, the Company has $<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_c20230630_z94IMB1nyNJb" title="Cash equivalents"><span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zplYfw6gZkV8" title="Cash equivalents">2,000</span></span> in cash equivalents, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_zjzymXTvOtHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_z54nTxgpQFa9">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zsLcZEJjZsec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zeZj7rvBhYG6">Accounts Receivable</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts by specific customer identification. If market conditions decline, actual collections may not meet expectations and may result in decreased cash flow and increased bad debt expense. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zIaCYiaX9LBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zGgU6X4vuEWj">Revenue Recognition</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its revenues under FASB ASC 606, which is a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company considers revenue realized or realizable and earned when all the five following criteria are met: (1) Identify the Contract with a Customer, (2) Identify the Performance Obligations in the Contract, (3) Determine the Transaction Price, (4) Allocate the Transaction Price to the Performance Obligations in the Contract, and (5) Recognize Revenue When (or As) the Entity Satisfies a Performance Obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes consulting income when the services are performed, and performance obligations are satisfied over time or point of time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_ztHqdQ2i5ML1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_864_zjO12Q23IAQe">Income Taxes</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has evaluated and concluded that there are no material tax positions requiring recognition in the Company’s unaudited condensed consolidated financial statements as of June 30, 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s 2020, 2021, and 2022 tax returns remain open for audit for Federal and State taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--MarketableSecuritiesPolicy_z6NkjLqGWoS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zNyN4k36Qbmh">Marketable Securities</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for marketable and available-for-sale securities under ASU 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its investment in EZFill Holdings, Inc. as available-for-sale securities pursuant to the S-1 Registration Statement declared effective on September 14, 2021, therefore, the unrealized gain (loss) on the available-for-sale securities during the six months ended June 30, 2023, and 2022 has been recorded in Other Income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 2, 2020, the Company received <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20201202__20201202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EZFillHoldingsIncMember_zJdN1tKiw8Sb" title="Received for shares">1,000,000</span> shares from EZFill Holdings, Inc, a related party, for past services, with each share valued at $<span id="xdx_907_eus-gaap--SharePrice_iI_c20201202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EZFillHoldingsIncMember_zs7yfzHwMMu6" title="Share price">1</span> each. At the time of acquiring these shares, EZFill Holdings, Inc. was not a publicly traded company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2021, the S-1 Registration Statement for EZFill Holdings, Inc. was declared effective by the U.S. Securities and Exchange Commission. As a result of becoming a publicly traded company, our investment is now recorded at fair value as available-for-sale securities on June 30, 2023, with the gains and losses being recorded through other income on the consolidated statements of operations for the three then ended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2020, the Company executed a two (2) year, third-party consulting agreement for various corporate services. The current service agreement has expired effective November 18, 2022. In connection with this agreement, and with the effectiveness of the Company’s Form S-1 registration statement, the Company was entitled to compensation as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20221117__20221118_zyHY9YMyMyl3" title="Issuance of shares">1,000,000</span> shares of common stock having a fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221117__20221118_zpynHXZRbpRi" title="Issuance of value">1,000,000</span> ($<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20221118_zmX6rVi5cPUg" title="Shares issued price, per share">1.00</span>/share), each based on a recent cash price of the related party;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● a single payment of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20221117__20221118__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6To7Vl000fe">200,000</span>;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● during the first year of the agreement, $<span id="xdx_905_eus-gaap--SalariesAndWages_c20221117__20221118__srt--StatementScenarioAxis__custom--FirstYearMember__us-gaap--AwardDateAxis__custom--MonthlyMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zI8cgtRzIce6" title="Salaries and wages">25,000</span> per month, with the 1<sup>st</sup> payment due 30 days after the completion of the Company’s IPO;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● during the second year of the agreement, $<span id="xdx_90A_eus-gaap--SalariesAndWages_c20221117__20221118__srt--StatementScenarioAxis__custom--SecondYearMember__us-gaap--AwardDateAxis__custom--MonthlyMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLbHiLwccmIe" title="Salaries and wages">22,500</span> per month; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● on each anniversary of the agreement, <span id="xdx_902_eus-gaap--SalariesAndWages_c20221117__20221118__srt--StatementScenarioAxis__custom--EachAnniversaryMember_z4FvzzCCbKij" title="Salaries and wages">500,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2023, the Company owned <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20230630_zMM9U8srO7A2" title="Fair value of investment cost">66,432</span> shares and the fair value of the investment in EZFill Holdings, Inc. was reported on the balance sheet as Investment at fair value - related party totaling $<span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20230630_zbqMOAOwGDih" title="Fair value of investment cost">155,452</span> ($<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20230630_zaLrNRJbTz23" title="Shares issued price, per share">2.34</span>/share). The Company recorded an adjustment of $<span id="xdx_90B_eus-gaap--DebtSecuritiesUnrealizedGainLoss_c20230101__20230630_ziO1HQFnkKF" title="Unrealized loss on securities">6,644</span> for the six months ending June 30, 2023, as unrealized gain on securities. EZFill Holdings Inc. reported a <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20230101__20230630_zNFbuabeMhq8" title="Reverse stock split description">1 share for 8 share reverse stock split</span> on April 26, 2023, which affected the total number of shares reported as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--InvestmentRelatedPartiesPolicyTextBlock_zQgzNyjEgzz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zqx2TJt9Bsgc">Investments – Related Parties</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--EquityMethodInvestmentPercentageDescription_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zk085RKbl5G7" title="Equity method investment percentage, description">When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company holds one investment as of June 30, 2023, and one investment as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--InvestmentPolicyTextBlock_zLoHVworvVe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zIguejAKVQF5">Investments</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 29, 2021, the Company received <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210129__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PharmacyNo27LtdMember_zQsbdTcQifie" title="Ownership percentage">20</span>% ownership of Pharmacy No, 27, Ltd, a company based in Israel, as part of a Note Receivable from a third party (see Note 5). As of June 30, 2023, the investment has a fair value of $<span id="xdx_902_eus-gaap--Investments_iI_c20230630_zePRU8Czmom" title="Investments">0</span>, based upon the quoted closing trading price and it is recorded on our consolidated balance sheet using the equity method. During each six months ended June 30, 2023, the Company recorded $<span id="xdx_909_ecustom--UnrealizedLossOnInvestments_iI_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PharmacyNo27LtdMember_z7wMY7AvtjY2" title="Unrealized loss on investments">0</span> of unrealized loss from this investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zfkUTcFFSmH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zoS8FhHFMt15">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2023, and December 31, 2022, the carrying value of marketable securities was $<span id="xdx_90A_eus-gaap--MarketableSecurities_iI_pp0p0_c20230630_zG4wrWNR21F6" title="Marketable securities">155,452</span> and $<span id="xdx_901_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231_zWuL30tH423b" title="Marketable securities">148,808</span>, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zXVyXwV75RL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_z21ZwHNDTvQj">Principles of Consolidation</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the Company and its wholly owned corporate subsidiaries, Balance Labs LLC., from October 12, 2015, Balance AgroTech Co., from July 11, 2016, Advanced Auto Tech Co., from May 10, 2016, Balance Cannabis Co., from May 13, 2016, and Balance Medical Marijuana Co from December 22, 2015. All intercompany transactions are eliminated. The Company’s four subsidiaries, Balance AgroTech Co., Advanced AutoTech Co., Balance Cannabis Co., and Balance Medical Marijuana Co. are dormant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsEoKSuh5cc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zua96UsoT057">Net Income (Loss) Per Common Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and warrants from convertible debentures outstanding during the periods. The effect of <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z37zFfemxAa7" title="Antidilutive securities excluded from earnings per share amount">0</span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOn8PMWreK" title="Antidilutive securities excluded from earnings per share amount">40,000</span> warrants and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zXzThpEJaUi" title="Antidilutive securities excluded from earnings per share amount">3,698,494</span> and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zFhyggAhnKVj" title="Antidilutive securities excluded from earnings per share amount">3,526,378</span> shares from convertible notes payable for the six months ended June 30, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoNAVxd5BIQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zeJpbjlX8ub3">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has computed the fair value of warrants granted using the Black-Scholes option pricing model. The expected term used for warrants is the contractual life. Since the Company’s stock has not been publicly traded for a sufficiently long period, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z2RwCDaxyFYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_z461QVjkW1Xb">Fair Value of Financial Instruments</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures its financial assets and liabilities in accordance with GAAP. For certain of our financial instruments, including cash, accounts payable, and the short-term portion of long-term debt, the carrying amounts approximate fair value due to their short maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We adopted accounting guidance for financial and non-financial assets and liabilities (ASC 820). This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_z8bJrbvTqWS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zAgLhaf75Ymd" style="display: none">Schedule of Fair Value of Assets on Recurring Basis</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Fair-value – equity securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXrDFCQd5aA7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">155,452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0QEmfgqf5y6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">155,452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVy3CmqrQB7i" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">     <span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ztRiayfNmOvi" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">     <span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7UKhU7Zg9P1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">155,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUzICXdJwgw5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">155,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGMN64J4u3A7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNkg2CzdUEHj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Fair-value – equity securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSdYYATUlsx5" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">148,808</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJpKL7BHY1s4" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">148,808</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpFltL45JxEe" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">      <span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znWAn3AAQjcj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">      <span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN1hcmO5qin3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">148,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkedCMqxQVy8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">148,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuE7OEuuIvli" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD2kyEJzRpxi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zl557xsoqvfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its investment in EzFill Holdings, Inc. (“EzFill”) as available-for-sale securities. Since the investment is valued based on quoted market price using observable inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZOAmhIqalTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zBBJfR0pWiG2">Business Segments</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in <span id="xdx_900_eus-gaap--NumberOfOperatingSegments_dc_uint_c20230101__20230630_zRkeb1MgIhF7" title="Number of operating segment">one</span> segment and therefore segment information is not presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zRH6WMwOLMXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_864_zb18z0K6a3ge">Advertising, Marketing and Promotional Costs</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising, marketing, and promotional expenses are expensed as incurred and are included in selling, general and administrative expenses on the accompanying unaudited condensed consolidated statement of operations. For the six months ended June 30, 2023, and June 30, 2022, advertising, marketing, and promotion expense was $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_pp0p0_c20230101__20230630_zRoUlC6Zvccf" title="Advertising, marketing and promotion expense">2,394</span> and $<span id="xdx_906_eus-gaap--MarketingAndAdvertisingExpense_pp0p0_c20220101__20220630_zJRtgFyeORr7" title="Advertising, marketing and promotion expense">48</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zJRxV3lVwfM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_862_z6LnrEBOvZH">Property and equipment</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consist of furniture and office equipment and is stated at cost less accumulated depreciation. Depreciation is determined by using the straight-line method for furniture and office equipment, over the estimated useful lives of the related assets, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20230630__srt--RangeAxis__srt--MinimumMember_zxHWNu8Fubkj" title="Property, plant and equipment, estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0564">three</span></span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20230630__srt--RangeAxis__srt--MaximumMember_zXw4hm7LukRa" title="Property, plant and equipment, estimated useful life">five years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the related assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKqicJHzVdGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment as of June 30, 2023, and December 31, 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zO7pLHpieMua" style="display: none">Schedule of Property and Equipment</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230630_zevdi82b6Zk3" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zXY8KahsviHa" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WebsiteMember_zLLzB2SMPD7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Website</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,336</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,336</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zaO4Dsx038Li" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Computer equipment &amp; Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,358</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zw3eW8Q4WGDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Furniture</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,622</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,622</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzr0L_z6x0ij9cUqE3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,316</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzr0L_zIwMAzGjJF8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,316</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,316</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzr0L_zPcYy5LAlyY" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Property and Equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z7RVH9deWtlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the six months ended June 30, 2023, and 2022 totaled $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_dxL_c20230101__20230630_z0TKhUHKyKUd" title="Depreciation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0588">0</span></span> and $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_dxL_c20220101__20220630_zj0LfeajHl85" title="Depreciation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0590">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0YRc4fPAZo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zxrMdcWo0djk">Recently Issued Accounting Pronouncements</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all new accounting standards that are in effect and may impact its unaudited condensed consolidated financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.</span></p> <p id="xdx_859_zHv2iuGr9od3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zK1cx5CDyC29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_861_zennhR2udxrb">Cash and Cash Equivalents</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of 90 days or less to be cash equivalents. At June 30, 2023, and December 31, 2022, the Company has $<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_c20230630_z94IMB1nyNJb" title="Cash equivalents"><span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zplYfw6gZkV8" title="Cash equivalents">2,000</span></span> in cash equivalents, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2000 2000 <p id="xdx_846_eus-gaap--UseOfEstimates_zjzymXTvOtHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_z54nTxgpQFa9">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zsLcZEJjZsec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zeZj7rvBhYG6">Accounts Receivable</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts by specific customer identification. If market conditions decline, actual collections may not meet expectations and may result in decreased cash flow and increased bad debt expense. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zIaCYiaX9LBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zGgU6X4vuEWj">Revenue Recognition</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its revenues under FASB ASC 606, which is a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company considers revenue realized or realizable and earned when all the five following criteria are met: (1) Identify the Contract with a Customer, (2) Identify the Performance Obligations in the Contract, (3) Determine the Transaction Price, (4) Allocate the Transaction Price to the Performance Obligations in the Contract, and (5) Recognize Revenue When (or As) the Entity Satisfies a Performance Obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes consulting income when the services are performed, and performance obligations are satisfied over time or point of time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_ztHqdQ2i5ML1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_864_zjO12Q23IAQe">Income Taxes</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has evaluated and concluded that there are no material tax positions requiring recognition in the Company’s unaudited condensed consolidated financial statements as of June 30, 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s 2020, 2021, and 2022 tax returns remain open for audit for Federal and State taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--MarketableSecuritiesPolicy_z6NkjLqGWoS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zNyN4k36Qbmh">Marketable Securities</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for marketable and available-for-sale securities under ASU 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its investment in EZFill Holdings, Inc. as available-for-sale securities pursuant to the S-1 Registration Statement declared effective on September 14, 2021, therefore, the unrealized gain (loss) on the available-for-sale securities during the six months ended June 30, 2023, and 2022 has been recorded in Other Income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 2, 2020, the Company received <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20201202__20201202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EZFillHoldingsIncMember_zJdN1tKiw8Sb" title="Received for shares">1,000,000</span> shares from EZFill Holdings, Inc, a related party, for past services, with each share valued at $<span id="xdx_907_eus-gaap--SharePrice_iI_c20201202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EZFillHoldingsIncMember_zs7yfzHwMMu6" title="Share price">1</span> each. At the time of acquiring these shares, EZFill Holdings, Inc. was not a publicly traded company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2021, the S-1 Registration Statement for EZFill Holdings, Inc. was declared effective by the U.S. Securities and Exchange Commission. As a result of becoming a publicly traded company, our investment is now recorded at fair value as available-for-sale securities on June 30, 2023, with the gains and losses being recorded through other income on the consolidated statements of operations for the three then ended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2020, the Company executed a two (2) year, third-party consulting agreement for various corporate services. The current service agreement has expired effective November 18, 2022. In connection with this agreement, and with the effectiveness of the Company’s Form S-1 registration statement, the Company was entitled to compensation as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20221117__20221118_zyHY9YMyMyl3" title="Issuance of shares">1,000,000</span> shares of common stock having a fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221117__20221118_zpynHXZRbpRi" title="Issuance of value">1,000,000</span> ($<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20221118_zmX6rVi5cPUg" title="Shares issued price, per share">1.00</span>/share), each based on a recent cash price of the related party;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● a single payment of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20221117__20221118__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6To7Vl000fe">200,000</span>;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● during the first year of the agreement, $<span id="xdx_905_eus-gaap--SalariesAndWages_c20221117__20221118__srt--StatementScenarioAxis__custom--FirstYearMember__us-gaap--AwardDateAxis__custom--MonthlyMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zI8cgtRzIce6" title="Salaries and wages">25,000</span> per month, with the 1<sup>st</sup> payment due 30 days after the completion of the Company’s IPO;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● during the second year of the agreement, $<span id="xdx_90A_eus-gaap--SalariesAndWages_c20221117__20221118__srt--StatementScenarioAxis__custom--SecondYearMember__us-gaap--AwardDateAxis__custom--MonthlyMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLbHiLwccmIe" title="Salaries and wages">22,500</span> per month; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● on each anniversary of the agreement, <span id="xdx_902_eus-gaap--SalariesAndWages_c20221117__20221118__srt--StatementScenarioAxis__custom--EachAnniversaryMember_z4FvzzCCbKij" title="Salaries and wages">500,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2023, the Company owned <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20230630_zMM9U8srO7A2" title="Fair value of investment cost">66,432</span> shares and the fair value of the investment in EZFill Holdings, Inc. was reported on the balance sheet as Investment at fair value - related party totaling $<span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20230630_zbqMOAOwGDih" title="Fair value of investment cost">155,452</span> ($<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20230630_zaLrNRJbTz23" title="Shares issued price, per share">2.34</span>/share). The Company recorded an adjustment of $<span id="xdx_90B_eus-gaap--DebtSecuritiesUnrealizedGainLoss_c20230101__20230630_ziO1HQFnkKF" title="Unrealized loss on securities">6,644</span> for the six months ending June 30, 2023, as unrealized gain on securities. EZFill Holdings Inc. reported a <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20230101__20230630_zNFbuabeMhq8" title="Reverse stock split description">1 share for 8 share reverse stock split</span> on April 26, 2023, which affected the total number of shares reported as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000000 1 1000000 1000000 1.00 200000 25000 22500 500000 66432 155452 2.34 6644 1 share for 8 share reverse stock split <p id="xdx_847_ecustom--InvestmentRelatedPartiesPolicyTextBlock_zQgzNyjEgzz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zqx2TJt9Bsgc">Investments – Related Parties</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--EquityMethodInvestmentPercentageDescription_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zk085RKbl5G7" title="Equity method investment percentage, description">When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company holds one investment as of June 30, 2023, and one investment as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein <p id="xdx_84E_eus-gaap--InvestmentPolicyTextBlock_zLoHVworvVe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zIguejAKVQF5">Investments</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 29, 2021, the Company received <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210129__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PharmacyNo27LtdMember_zQsbdTcQifie" title="Ownership percentage">20</span>% ownership of Pharmacy No, 27, Ltd, a company based in Israel, as part of a Note Receivable from a third party (see Note 5). As of June 30, 2023, the investment has a fair value of $<span id="xdx_902_eus-gaap--Investments_iI_c20230630_zePRU8Czmom" title="Investments">0</span>, based upon the quoted closing trading price and it is recorded on our consolidated balance sheet using the equity method. During each six months ended June 30, 2023, the Company recorded $<span id="xdx_909_ecustom--UnrealizedLossOnInvestments_iI_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PharmacyNo27LtdMember_z7wMY7AvtjY2" title="Unrealized loss on investments">0</span> of unrealized loss from this investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.20 0 0 <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zfkUTcFFSmH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zoS8FhHFMt15">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2023, and December 31, 2022, the carrying value of marketable securities was $<span id="xdx_90A_eus-gaap--MarketableSecurities_iI_pp0p0_c20230630_zG4wrWNR21F6" title="Marketable securities">155,452</span> and $<span id="xdx_901_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231_zWuL30tH423b" title="Marketable securities">148,808</span>, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 155452 148808 <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zXVyXwV75RL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_z21ZwHNDTvQj">Principles of Consolidation</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the Company and its wholly owned corporate subsidiaries, Balance Labs LLC., from October 12, 2015, Balance AgroTech Co., from July 11, 2016, Advanced Auto Tech Co., from May 10, 2016, Balance Cannabis Co., from May 13, 2016, and Balance Medical Marijuana Co from December 22, 2015. All intercompany transactions are eliminated. The Company’s four subsidiaries, Balance AgroTech Co., Advanced AutoTech Co., Balance Cannabis Co., and Balance Medical Marijuana Co. are dormant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsEoKSuh5cc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zua96UsoT057">Net Income (Loss) Per Common Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and warrants from convertible debentures outstanding during the periods. The effect of <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z37zFfemxAa7" title="Antidilutive securities excluded from earnings per share amount">0</span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOn8PMWreK" title="Antidilutive securities excluded from earnings per share amount">40,000</span> warrants and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zXzThpEJaUi" title="Antidilutive securities excluded from earnings per share amount">3,698,494</span> and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zFhyggAhnKVj" title="Antidilutive securities excluded from earnings per share amount">3,526,378</span> shares from convertible notes payable for the six months ended June 30, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 40000 3698494 3526378 <p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoNAVxd5BIQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zeJpbjlX8ub3">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has computed the fair value of warrants granted using the Black-Scholes option pricing model. The expected term used for warrants is the contractual life. Since the Company’s stock has not been publicly traded for a sufficiently long period, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z2RwCDaxyFYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_z461QVjkW1Xb">Fair Value of Financial Instruments</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures its financial assets and liabilities in accordance with GAAP. For certain of our financial instruments, including cash, accounts payable, and the short-term portion of long-term debt, the carrying amounts approximate fair value due to their short maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We adopted accounting guidance for financial and non-financial assets and liabilities (ASC 820). This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_z8bJrbvTqWS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zAgLhaf75Ymd" style="display: none">Schedule of Fair Value of Assets on Recurring Basis</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Fair-value – equity securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXrDFCQd5aA7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">155,452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0QEmfgqf5y6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">155,452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVy3CmqrQB7i" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">     <span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ztRiayfNmOvi" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">     <span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7UKhU7Zg9P1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">155,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUzICXdJwgw5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">155,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGMN64J4u3A7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNkg2CzdUEHj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Fair-value – equity securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSdYYATUlsx5" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">148,808</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJpKL7BHY1s4" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">148,808</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpFltL45JxEe" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">      <span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znWAn3AAQjcj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">      <span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN1hcmO5qin3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">148,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkedCMqxQVy8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">148,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuE7OEuuIvli" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD2kyEJzRpxi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zl557xsoqvfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its investment in EzFill Holdings, Inc. (“EzFill”) as available-for-sale securities. Since the investment is valued based on quoted market price using observable inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_z8bJrbvTqWS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zAgLhaf75Ymd" style="display: none">Schedule of Fair Value of Assets on Recurring Basis</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Fair-value – equity securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXrDFCQd5aA7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">155,452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0QEmfgqf5y6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">155,452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVy3CmqrQB7i" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">     <span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ztRiayfNmOvi" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">     <span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7UKhU7Zg9P1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">155,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUzICXdJwgw5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">155,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGMN64J4u3A7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNkg2CzdUEHj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain assets of the Company’s measured and recorded at fair value on the Company’s balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Fair-value – equity securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSdYYATUlsx5" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">148,808</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJpKL7BHY1s4" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">148,808</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpFltL45JxEe" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">      <span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znWAn3AAQjcj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair-value - equity securities">      <span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN1hcmO5qin3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">148,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkedCMqxQVy8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value">148,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuE7OEuuIvli" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD2kyEJzRpxi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 155452 155452 155452 155452 148808 148808 148808 148808 <p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZOAmhIqalTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zBBJfR0pWiG2">Business Segments</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in <span id="xdx_900_eus-gaap--NumberOfOperatingSegments_dc_uint_c20230101__20230630_zRkeb1MgIhF7" title="Number of operating segment">one</span> segment and therefore segment information is not presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zRH6WMwOLMXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_864_zb18z0K6a3ge">Advertising, Marketing and Promotional Costs</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising, marketing, and promotional expenses are expensed as incurred and are included in selling, general and administrative expenses on the accompanying unaudited condensed consolidated statement of operations. For the six months ended June 30, 2023, and June 30, 2022, advertising, marketing, and promotion expense was $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_pp0p0_c20230101__20230630_zRoUlC6Zvccf" title="Advertising, marketing and promotion expense">2,394</span> and $<span id="xdx_906_eus-gaap--MarketingAndAdvertisingExpense_pp0p0_c20220101__20220630_zJRtgFyeORr7" title="Advertising, marketing and promotion expense">48</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2394 48 <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zJRxV3lVwfM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_862_z6LnrEBOvZH">Property and equipment</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consist of furniture and office equipment and is stated at cost less accumulated depreciation. Depreciation is determined by using the straight-line method for furniture and office equipment, over the estimated useful lives of the related assets, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20230630__srt--RangeAxis__srt--MinimumMember_zxHWNu8Fubkj" title="Property, plant and equipment, estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0564">three</span></span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20230630__srt--RangeAxis__srt--MaximumMember_zXw4hm7LukRa" title="Property, plant and equipment, estimated useful life">five years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the related assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKqicJHzVdGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment as of June 30, 2023, and December 31, 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zO7pLHpieMua" style="display: none">Schedule of Property and Equipment</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230630_zevdi82b6Zk3" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zXY8KahsviHa" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WebsiteMember_zLLzB2SMPD7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Website</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,336</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,336</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zaO4Dsx038Li" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Computer equipment &amp; Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,358</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zw3eW8Q4WGDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Furniture</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,622</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,622</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzr0L_z6x0ij9cUqE3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,316</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzr0L_zIwMAzGjJF8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,316</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,316</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzr0L_zPcYy5LAlyY" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Property and Equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z7RVH9deWtlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the six months ended June 30, 2023, and 2022 totaled $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_dxL_c20230101__20230630_z0TKhUHKyKUd" title="Depreciation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0588">0</span></span> and $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_dxL_c20220101__20220630_zj0LfeajHl85" title="Depreciation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0590">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKqicJHzVdGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment as of June 30, 2023, and December 31, 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zO7pLHpieMua" style="display: none">Schedule of Property and Equipment</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230630_zevdi82b6Zk3" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zXY8KahsviHa" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WebsiteMember_zLLzB2SMPD7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Website</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,336</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,336</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zaO4Dsx038Li" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Computer equipment &amp; Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,358</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zw3eW8Q4WGDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Furniture</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,622</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,622</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzr0L_z6x0ij9cUqE3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,316</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzr0L_zIwMAzGjJF8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,316</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,316</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzr0L_zPcYy5LAlyY" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Property and Equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1336 1336 5358 5358 4622 4622 11316 11316 11316 11316 <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0YRc4fPAZo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zxrMdcWo0djk">Recently Issued Accounting Pronouncements</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all new accounting standards that are in effect and may impact its unaudited condensed consolidated financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations.</span></p> <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs47fQ2wUi73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_828_zLSL0b2Kej43">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Authorized Capital</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230630_zwiH7EFnSLMd" title="Common stock, shares authorized">500,000,000</span> shares of common stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230630_zFvkd5fgCZ0f" title="Common stock, par value">0.0001</span> par value, and <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20230630_zl2R6AgV7c16" title="Preferred stock, shares authorized">50,000,000</span> shares of preferred stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230630_z83HiZwQZVLa" title="Preferred stock, par value">0.0001</span> par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2019, the Company received $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_z4uhvDUAVuvl" title="Debt instrument, face amount">40,000</span> from The Sammy Farkas Foundation in exchange for a promissory note which bears <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zOiXXp6l1Bjh" title="Interest rate of related party loan">12</span>% interest per annum and matured on October 10, 2020, or upon the Company raising $<span id="xdx_908_eus-gaap--OtherLiabilities_iI_pp0p0_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zPh3L7zBEhB3" title="Due to related parties">500,000</span> from outside investors, whichever occurs first. In conjunction with The Sammy Farkas Foundation agreement the Company issued warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zVAVO2Y6gup8" title="Warrants issued to purchase of common stock shares">40,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zqMXjhyf1S5h" title="Warrants exercise price per share">1.00</span> per share which expired on October 10, 2022. As of June 30, 2023, there are no warrants outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 500000000 0.0001 50000000 0.0001 40000 0.12 500000 40000 1.00 <p id="xdx_807_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_z0ExqIPvjOUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_82E_z3AQ5KlgZNFl">Note Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2021, Balance Labs Inc. made a loan to Four Acquisition, Ltd., an unrelated party in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210930__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_zNMyp4HH5wS5" title="Debt Instrument face amount">22,000</span> which loan has an interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210930__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_zlTsltnAOG8c" title="Debt instrument interest rate stated percentage">10</span>% per annum and a maturity date of <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210929__20210930__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_zYJhTh4WZHya" title="Debt maturity date">September 30, 2022</span>. As of June 30, 2023, this receivable is fully reserved against. For the six months ended June 30, 2023 and 2022, the Company recorded $<span id="xdx_905_eus-gaap--InterestIncomeOperating_c20230101__20230630__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_z9c7qrRrBvYg" title="Interest income related party">0</span> and $<span id="xdx_901_eus-gaap--InterestIncomeOperating_c20220101__20220630__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_zX0BbDJ9I8E8" title="Interest income related party">0</span>, respectively, of interest income in relation to this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 29, 2021, Balance Labs Inc. made a loan to Four Acquisitions Ltd., an unrelated party in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210129__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_zXifqmY1yXfi" title="Debt instrument face amount">119,000</span> which has an interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210129__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_z193Er8TVJ6d" title="Debt instrument interest rate stated percentage">10</span>% per annum and a maturity date of January 28, 2022. Additionally, in connection with the loan, the Company received a <span id="xdx_908_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_pid_dp_uPure_c20210129__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_zNfSmrPLhFye" title="Equity interest acquire percentage">20</span>% interest in the recently acquired business and related assets of Four Acquisitions Ltd. Initially, this investment had a purchase price of $<span id="xdx_909_eus-gaap--InvestmentsFairValueDisclosure_iI_c20210129__us-gaap--BusinessAcquisitionAxis__custom--FourAcquisitionsLtdMember_zvX7xqTNo402" title="Investments fair value disclosure">43,000</span>, which was recorded as a discount from the note which will be amortized over the life of the note. The Company recorded an allowance of <span id="xdx_90F_ecustom--NotesReceivableUnamortizedAllowanceCurrentPercentage_iI_dp_uPure_c20230630_zLEjXBdXHzX" title="Notes receivable unamortized allowance current, percentage">100</span>% against this receivable of $<span id="xdx_909_ecustom--NotesReceivableUnamortizedAllowanceCurrent_iI_c20230630_zwze0VFjoGI2" title="Notes receivable unamortized allowance current">141,000</span> as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 22000 0.10 2022-09-30 0 0 119000 0.10 0.20 43000 1 141000 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zySMtCZlK6za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_829_zjvVdUe52NXh">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s CEO earned $<span id="xdx_901_eus-gaap--OfficersCompensation_pp0p0_c20230101__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zQbonWoltwZ5" title="Officers compensation">10,000</span> per month through June 30, 2022. This agreement was terminated effective June 30, 2022. The following compensation was recorded within general and administrative expenses – related parties on the statements of operations: $<span id="xdx_907_eus-gaap--SellingGeneralAndAdministrativeExpense_pp0p0_c20230101__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zz3SvcAV7qMl" title="General and administrative expenses - related party">0</span> and $<span id="xdx_90C_eus-gaap--SellingGeneralAndAdministrativeExpense_pp0p0_c20220101__20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrhMGlavNLjd" title="General and administrative expenses - related party">30,000</span> for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and December 31, 2022, $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_znITfpHQ1Odk" title="Accounts payable related party">0</span> and $<span id="xdx_90A_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8la4oRCLV24" title="Accounts payable related party">30,000</span>, respectively, of compensation was unpaid and was included in accounts payable – related party on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2016, the Company received $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20160328__20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zfzr92h6TIwk" title="Proceeds from convertible debt">500,000</span> from Newell Trading Group in exchange for a convertible debenture due April 2, 2017, bearing interest at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zTuBNaIMsj2c" title="Debt instrument interest rate percentage">10</span>% and convertible into common stock at $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zvUWVaNoDufj" title="Debt instrument convertible conversion price">.25</span> per share unless the note is paid by the Company prior to the election of the holder to convert. The Company recognized a beneficial conversion feature expense of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20160328__20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_ztV26cYClVA2" title="Debt instrument, convertible, beneficial conversion feature">500,000</span> that has been fully amortized. As of June 30, 2023 and December 31, 2022, accrued interest on the note is $<span id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zC1WN3GsnpYe" title="Interest payable">350,000</span> and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zMidPw82ZRGd" title="Interest payable">300,000</span>, respectively. On October 3, 2019, Newell Trading Group assigned its rights and interests in its $<span id="xdx_909_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20191002__20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zP7y8HPk8FFb" title="Debt instrument, increase (decrease), net">500,000</span> convertible debenture to the Sammy Farkas Foundation Inc., (the “Foundation”), a related party. The convertible note payable, net of debt discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zB0IHr7pizUl" title="Debt instrument discount">14,175</span> and $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_ztuYWHHYNoki" title="Debt instrument discount">19,845</span> as of June 30, 2023 and December 31, 2022 of $<span id="xdx_909_eus-gaap--LongTermDebt_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zxuZReGruede" title="Long term debt">485,825</span> and $<span id="xdx_903_eus-gaap--LongTermDebt_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zhZUizYsNki9" title="Long term debt">480,155</span>, respectively was recorded under long term liability on the balance sheet.</span></p> <p id="xdx_890_eus-gaap--ConvertibleDebtTableTextBlock_hus-gaap--RelatedPartyTransactionAxis__custom--NewellTradingGroupMember_zQuBXBuG7oa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zaz6Aw4TkQlh" style="display: none">Schedule of Convertible Note Payable - Long Term</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230630_zER78cgMQu9b" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_z1lAUVogTCZ6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentFaceAmount_iI_maCLTNPz3Zy_zW7G5URfqwpb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16<sup>th </sup>Avenues Associates</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iNI_di_msCLTNPz3Zy_zcEtQDe9Rum" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleLongTermNotesPayable_iTI_mtCLTNPz3Zy_zY15QHtdK9wl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Convertible note payable – long term</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">485,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">480,155</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_z82rd2s79rV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Foundation then entered into an agreement with the Company to extend the maturity date of the convertible debenture to <span id="xdx_90A_ecustom--DebtInstrumentExtendedMaturityDate_c20191002__20191003__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_ze5sgwoTUtIf" title="Debt instrument maturity rate">October 10, 2024</span> in exchange for <span id="xdx_90D_ecustom--NumberOfSharesExchange_c20191002__20191003__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zk2ChyHtXwjb" title="Number of shares exchange">54,000</span> shares of the Company’s stock. The shares have a fair value of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20191003__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_z01vEZw1OfB8" title="Debt instrument unamortized discount">56,700</span> which was recorded as a debt discount and was being amortized over the life of the extension. On November 11, 2019, The Sammy Farkas Foundation transferred all the rights and interests of the note to another party, 16th Avenue Associates, a non-related party company. The terms remain the same and the transfer has no effect on the financial statements. During the six months ended June 30, 2023 and December 31, 2022, the Company amortized $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zuD7rRPL6795" title="Amortization of debt discount premium">5,670</span> and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zxLkV2MCJ3G2" title="Amortization of debt discount premium">5,670</span>, respectively of debt discount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2016, 2017, and 2019 Balance Group LLC loaned an additional $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20161231__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_zym73iMEIChi" title="Convertible notes payable"><span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20171231__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_zzPMk6RdhrZb" title="Convertible notes payable"><span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20191231__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_z8fJ2fqCfeyh" title="Convertible notes payable">66,850</span></span></span> to the Company. The notes are in default and have an accrued interest balance of $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230630__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_zIH7NvmCR3hd" title="Interest payable">29,481</span>. The note balance of $<span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_c20230630__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_zntDKD79FZZ6" title="Convertible notes payable"><span id="xdx_905_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_c20221231__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_z7nKhReQnMce" title="Convertible notes payable">66,850</span></span> is included in the note payable – related party in current liability as of June 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2019, the Company received $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zFkb1XnzxVnc" title="Debt instrument face amount">40,000</span> from The Foundation in exchange for a promissory note which bears <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zecKHYIhm6fl" title="Debt stated percentage">12</span>% interest per annum and matured on October 10, 2020 or upon the Company raising $<span id="xdx_908_eus-gaap--OtherLiabilities_iI_c20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zGLsScqXYTPi" title="Due to related parties">500,000</span> from outside investors, whichever occurs first. The promissory note is currently in default, and as of June 30, 2023, accrued interest on the note is $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zG9hRIzxP4be" title="Interest payable">20,818</span>. The note balance of $<span id="xdx_905_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zD9NAw0qrvKi" title="Debt instrument face amount"><span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zngaBTLYZs49" title="Debt instrument face amount">40,000</span></span> is included in the note payable – related party in current liability as of June 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The promissory note comes with a warrant to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20191003__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztuGiCOUpRdc" title="Class of warrants">40,000</span> shares of the Company’s stock with an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191003__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqEzjSBJx5jf" title="Exercise price">1.00</span> per share and expired on October 10, 2022. The warrants had a relative fair value of $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z8l112wWbsU" title="Fair value of warrants">8,283</span>, which was recorded as a debt discount and fully amortized.</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zTQVpnHIUfY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zenxGlKd9H5l" style="display: none">Schedule of Note Payable - Related Party</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_zLSMVvYcFNc5" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zjTrwynAcqXe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionAxis__custom--BalanceGroupLLCMember_zf4XoHsedy8a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance Group LLC</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">66,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">66,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionAxis__custom--FoundationMember_zEGBwcTuIdD3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">The Foundation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_zV7pa2nGpwa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Note Payable – related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">106,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">106,850</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_zZBj0Caheipg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2021, the Company received $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_pp0p0_c20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCP48VQ7qaj1" title="Due to related parties">50,000</span> from the CEO in exchange for a convertible promissory note with a face value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zkYUveRaNMag" title="Debt instrument, face amount">53,192</span> which bears <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDI94R3AeYYa">12</span>% interest per annum and matures on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210626__20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLyNryxqoyq5" title="Debt instrument maturity date">June 27, 2022</span>, or upon the Company raising $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_pp0p0_c20210626__20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zxUDgCd2kzK1" title="Debt instrument, increase (decrease), net">250,000</span> from investors, whichever occurs first. The note balance of $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_c20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwf6aLedW933" title="Convertible notes payable">53,192</span> is included in the convertible notes payable - related party, net of debt discount of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zv4eccHW2nPk">0</span> and $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zAIbv6EjaFLi">3,428</span>, as of June 30, 2023, and December 31, 2022, respectively. The difference between the amount received and the face value of $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210626__20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zF7Ipak8jPm4" title="Amortization of debt discount">3,192</span> was recorded as a discount and is being amortized over the life of the note. Additionally, the note comes with a beneficial conversion feature of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20210626__20210627__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zi8751vLkQG5" title="Debt instrument, convertible, beneficial conversion">3,799</span> which was also recorded as a component of equity in 2021. As of June 30, 2023, the Company has accrued interest of $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zUp8JWLJOBc8" title="Interest payable">12,801</span> and is recorded in the accrued expenses on the balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2016, Balance Group LLC loaned $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20160930__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_z8zqbPZwFvw7" title="Convertible notes payable">120,000</span> as a convertible note payable to the Company at an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20160930__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_zuUiXt7Mzfl2" title="Debt instrument interest rate percentage">10</span>%, due on October 1, 2017. In addition, the Company issued <span id="xdx_901_ecustom--NumberOfWarrantsIssuedToRelatedParty_iI_c20210930__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_z31Ioy83oXA8" title="Number of warrants issued to related party">600,000</span> warrants at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_zrf86cPlW6t" title="Warrants exercise price per share">1</span> which expired on September 30, 2021 (See Note 9). The note is currently in default and is currently recorded under convertible payable – related party in current liabilities in the balance sheet. The accrued interest balance of $<span id="xdx_900_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20230101__20230630__srt--ConsolidatedEntitiesAxis__custom--BalanceGroupLLCMember_zLDUEp6DPemh" title="Accrued interest">81,008</span> is recorded in the accrued expenses on the balance sheet as of June 30, 2023.</span></p> <p id="xdx_89F_ecustom--ConvertibleNotesPayableRelatedPartyTableTextBlock_zIv19gFlmLt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zKUYaEn9ZMIh" style="display: none">Schedule of Convertible Note Payable - Related Party</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230630_zPg089q6VWKj" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zrIzp10iycm3" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_ecustom--DueToRelatedPartyCurrent_iI_hus-gaap--RelatedPartyTransactionAxis__custom--BalanceGroupLLCMember_zbDFBmfaKzZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance Group LLC</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DueToRelatedPartyCurrent_iI_hsrt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5JjyNRulfck" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Note Payable from CEO</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,192</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,192</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DueToRelatedPartyCurrent_iI_zqjZl5WGSyUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Convertible note payable- related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">173,192</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">173,192</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_ztB4WgFoRzl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 9, 2021, Krypto Ventures, Inc. formerly known as KryptoBank Co. issued an unsecured promissory note in the amount of $<span id="xdx_900_eus-gaap--UnsecuredDebt_iI_c20210709__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LyonsCapitalLLCMember_zJEY43mtarVh" title="Unsecured debt">25,000</span> to Lyons Capital LLC, a significant shareholder of Krypto Ventures, Inc. The note carries an interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210709__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LyonsCapitalLLCMember_zUffoXUN9tah" title="Debt instrument interest rate stated percentage">12</span>% and is due on the earlier of July 8, 2022, or the date on which Krypto Ventures, Inc. raises at least $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20210709__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KryptoVenturesIncMember_zDkAV3pPiGWb" title="Debt instrument face amount">200,000</span>. As of July 29, 2021, the Company has accrued interest of $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210729__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KryptoVenturesIncMember_zUGxU0vhPgoe" title="Interest payable current and noncurrent">164</span>. The note and accrued interest were deconsolidated as part of deconsolidation of Krypto Ventures, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021, Balance Labs Inc. made a loan to Krypto Ventures, Inc, formerly known as KryptoBank Co., a related party in the principal amount of $<span id="xdx_90F_eus-gaap--NotesReceivableNet_iI_c20210629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KryptoVenturesIncMember_z6VginHFecdd">25,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which loan has an interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LyonsCapitalLLCMember_z4TEarwUi3Ch">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per annum and a maturity date of <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210628__20210629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KryptoVenturesIncMember_z8c7UhBLRDCk">June 28, 2022</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023 and December 31, 2022, the CEO and companies controlled by the CEO have loaned the Company a total of $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_ztNj7etSOFO2">1,673,558 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in addition to the convertible notes discussed above. The loans carry an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zP97HH9I75ri">8</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and mature one year and one day from the date of the loan. These loans of $<span id="xdx_907_eus-gaap--OtherLiabilities_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zHlhjPGnYzL4">1,673,558 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the accrued interest on these loans of $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zBtFGAToEIk6">418,111 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are in default as of June 30, 2023. These loans of $<span id="xdx_90B_ecustom--DueToRelatedPartiesCurrentExcludeNotesPayableRelatedPartiesClassified_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zFo9UKWtZXN" title="Short-term advances from related party">1,673,558 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are in default and are reported under short -term advances from related party on the balance sheet as of June 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000 0 30000 0 30000 500000 0.10 0.25 500000 350000 300000 500000 14175 19845 485825 480155 <p id="xdx_890_eus-gaap--ConvertibleDebtTableTextBlock_hus-gaap--RelatedPartyTransactionAxis__custom--NewellTradingGroupMember_zQuBXBuG7oa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zaz6Aw4TkQlh" style="display: none">Schedule of Convertible Note Payable - Long Term</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230630_zER78cgMQu9b" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_z1lAUVogTCZ6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentFaceAmount_iI_maCLTNPz3Zy_zW7G5URfqwpb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16<sup>th </sup>Avenues Associates</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iNI_di_msCLTNPz3Zy_zcEtQDe9Rum" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleLongTermNotesPayable_iTI_mtCLTNPz3Zy_zY15QHtdK9wl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Convertible note payable – long term</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">485,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">480,155</td><td style="text-align: left"> </td></tr> </table> 500000 500000 14175 19845 485825 480155 2024-10-10 54000 56700 5670 5670 66850 66850 66850 29481 66850 66850 40000 0.12 500000 20818 40000 40000 40000 1.00 8283 <p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zTQVpnHIUfY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zenxGlKd9H5l" style="display: none">Schedule of Note Payable - Related Party</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_zLSMVvYcFNc5" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zjTrwynAcqXe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionAxis__custom--BalanceGroupLLCMember_zf4XoHsedy8a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance Group LLC</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">66,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">66,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionAxis__custom--FoundationMember_zEGBwcTuIdD3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">The Foundation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_zV7pa2nGpwa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Note Payable – related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">106,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">106,850</td><td style="text-align: left"> </td></tr> </table> 66850 66850 40000 40000 106850 106850 50000 53192 0.12 2022-06-27 250000 53192 0 3428 3192 3799 12801 120000 0.10 600000 1 81008 <p id="xdx_89F_ecustom--ConvertibleNotesPayableRelatedPartyTableTextBlock_zIv19gFlmLt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zKUYaEn9ZMIh" style="display: none">Schedule of Convertible Note Payable - Related Party</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230630_zPg089q6VWKj" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zrIzp10iycm3" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_ecustom--DueToRelatedPartyCurrent_iI_hus-gaap--RelatedPartyTransactionAxis__custom--BalanceGroupLLCMember_zbDFBmfaKzZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance Group LLC</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DueToRelatedPartyCurrent_iI_hsrt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5JjyNRulfck" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Note Payable from CEO</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,192</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,192</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DueToRelatedPartyCurrent_iI_zqjZl5WGSyUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Convertible note payable- related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">173,192</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">173,192</td><td style="text-align: left"> </td></tr> </table> 120000 120000 53192 53192 173192 173192 25000 0.12 200000 164 25000 0.12 2022-06-28 1673558 0.08 1673558 418111 1673558 <p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zFQMkNfQp6Wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_826_z94VdW3EJwik">Convertible Notes and Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Notes Payable</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For all information regarding the related party note payable see note 6.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALANCE LABS, INC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Convertible Notes Payable</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2016, the Company received $<span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20160328__20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zYWbpx2gAbA8">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from Newell Trading Group in exchange for a convertible debenture due <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20160328__20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zJlxWhvJIMm"><span style="-sec-ix-hidden: xdx2ixbrl0793">April 2, 2017,</span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">bearing interest at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zfOJvHEIUZOa">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and convertible into common stock at $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zHk9abIUgqFj">.25 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share unless the note is paid by the Company prior to the election of the holder to convert. The Company recognized a beneficial conversion feature expense of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20160328__20160401__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zQn2pFfU3ta7">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that has been fully amortized. As of December 31, 2021, accrued interest on the note is $<span id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zX3snY54xhz2">287,671</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. On October 3, 2019, Newell Trading Group assigned its rights and interests in its $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20191002__20191003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SammyFarkasFoundationIncMember_zMfHcAanLkhj">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convertible debenture to the Sammy Farkas Foundation Inc., (the “Foundation”), a related party. The Foundation then entered into an agreement with the Company to extend the maturity date of the convertible debenture to <span id="xdx_907_ecustom--DebtInstrumentExtendedMaturityDate_dd_c20191002__20191003__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zCDFxdntT4V1">October 10, 2024</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in exchange for <span id="xdx_902_ecustom--NumberOfSharesExchange_c20191002__20191003__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zEhS5yUomVee">54,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s stock. The shares have a fair value of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20191003__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_z2n4q3YZgxZ2">56,700 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recorded as a debt discount and amortized over the life of the extension. On November 11, 2019, The Sammy Farkas Foundation transferred all the rights and interests of the note to another party, 16<sup>th</sup> Avenue Associates. The terms remain the same and the transfer has no effect on the financial statements. The convertible note payable, net of debt discount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zRFe5yIzAZTd">14,175 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zWxzcENlAgoc">19,845 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of June 30, 2023 and December 31, 2022 was $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zAXlZ7TEKcj">485,825 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zcGLcM2iWMX7">480,155</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, and was recorded under long term liability on the balance sheet.</span></p> <p id="xdx_895_eus-gaap--ConvertibleDebtTableTextBlock_zVPhNwdym4Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zk7UIbwOHyi6" style="display: none">Schedule of Convertible Note Payable - Long Term</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_zg84aPhALgYg" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zvHE9QJlsnK" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentFaceAmount_iI_maCLTNPzOr0_zjpY9audgcql" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Newell Trading Group</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFaceAmount_iI_maCLTNPzOr0_zcO4sddm5KVa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible note payable – long term, gross</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iNI_di_msCLTNPzOr0_zJyBtXgIc4v8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--ConvertibleLongTermNotesPayable_iTI_mtCLTNPzOr0_zK9Gltdwz1tg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Convertible note payable – long term</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">485,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">480,155</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zrXPiKMiT9f3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 500000 0.10 0.25 500000 287671 500000 2024-10-10 54000 56700 14175 19845 485825 480155 <p id="xdx_895_eus-gaap--ConvertibleDebtTableTextBlock_zVPhNwdym4Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zk7UIbwOHyi6" style="display: none">Schedule of Convertible Note Payable - Long Term</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_zg84aPhALgYg" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/>2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zvHE9QJlsnK" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentFaceAmount_iI_maCLTNPzOr0_zjpY9audgcql" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Newell Trading Group</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFaceAmount_iI_maCLTNPzOr0_zcO4sddm5KVa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible note payable – long term, gross</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iNI_di_msCLTNPzOr0_zJyBtXgIc4v8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--ConvertibleLongTermNotesPayable_iTI_mtCLTNPzOr0_zK9Gltdwz1tg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Convertible note payable – long term</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">485,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">480,155</td><td style="text-align: left"> </td></tr> </table> 500000 500000 500000 500000 14175 19845 485825 480155 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zgC77hbOgIn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_821_zhqHpYsf0lQ">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Litigation, Claims and Assessments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s condensed consolidated financial position or results of operations.</span></p> EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 121 181 1 false 36 0 false 7 false false R1.htm 00000001 - Document - Cover Sheet http://balancelabs.co/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://balancelabs.co/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://balancelabs.co/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://balancelabs.co/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Sheet http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://balancelabs.co/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Business Organization and Nature of Operations Sheet http://balancelabs.co/role/BusinessOrganizationAndNatureOfOperations Business Organization and Nature of Operations Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://balancelabs.co/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://balancelabs.co/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Stockholders??? Equity Sheet http://balancelabs.co/role/StockholdersEquity Stockholders??? Equity Notes 10 false false R11.htm 00000011 - Disclosure - Note Receivable Sheet http://balancelabs.co/role/NoteReceivable Note Receivable Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://balancelabs.co/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Convertible Notes and Notes Payable Notes http://balancelabs.co/role/ConvertibleNotesAndNotesPayable Convertible Notes and Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://balancelabs.co/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://balancelabs.co/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://balancelabs.co/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Related Party Transactions (Tables) Sheet http://balancelabs.co/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://balancelabs.co/role/RelatedPartyTransactions 17 false false R18.htm 00000018 - Disclosure - Convertible Notes and Notes Payable (Tables) Notes http://balancelabs.co/role/ConvertibleNotesAndNotesPayableTables Convertible Notes and Notes Payable (Tables) Tables http://balancelabs.co/role/ConvertibleNotesAndNotesPayable 18 false false R19.htm 00000019 - Disclosure - Going Concern (Details Narrative) Sheet http://balancelabs.co/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://balancelabs.co/role/GoingConcern 19 false false R20.htm 00000020 - Disclosure - Schedule of Fair Value of Assets on Recurring Basis (Details) Sheet http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails Schedule of Fair Value of Assets on Recurring Basis (Details) Details 20 false false R21.htm 00000021 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://balancelabs.co/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://balancelabs.co/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - Note Receivable (Details Narrative) Sheet http://balancelabs.co/role/NoteReceivableDetailsNarrative Note Receivable (Details Narrative) Details http://balancelabs.co/role/NoteReceivable 24 false false R25.htm 00000025 - Disclosure - Schedule of Convertible Note Payable - Long Term (Details) Sheet http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails Schedule of Convertible Note Payable - Long Term (Details) Details 25 false false R26.htm 00000026 - Disclosure - Schedule of Note Payable - Related Party (Details) Sheet http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails Schedule of Note Payable - Related Party (Details) Details 26 false false R27.htm 00000027 - Disclosure - Schedule of Convertible Note Payable - Related Party (Details) Sheet http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails Schedule of Convertible Note Payable - Related Party (Details) Details 27 false false R28.htm 00000028 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://balancelabs.co/role/RelatedPartyTransactionsTables 28 false false R29.htm 00000029 - Disclosure - Convertible Notes and Notes Payable (Details Narrative) Notes http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative Convertible Notes and Notes Payable (Details Narrative) Details http://balancelabs.co/role/ConvertibleNotesAndNotesPayableTables 29 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentMaturityDate, us-gaap:PropertyPlantAndEquipmentUsefulLife - form10-q.htm 71, 76 form10-q.htm blnc-20230630.xsd blnc-20230630_cal.xml blnc-20230630_def.xml blnc-20230630_lab.xml blnc-20230630_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 47 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 404, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 121, "dts": { "calculationLink": { "local": [ "blnc-20230630_cal.xml" ] }, "definitionLink": { "local": [ "blnc-20230630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "blnc-20230630_lab.xml" ] }, "presentationLink": { "local": [ "blnc-20230630_pre.xml" ] }, "schema": { "local": [ "blnc-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 318, "entityCount": 1, "hidden": { "http://balancelabs.co/20230630": 9, "http://fasb.org/us-gaap/2023": 39, "http://xbrl.sec.gov/dei/2023": 4, "total": 52 }, "keyCustom": 20, "keyStandard": 161, "memberCustom": 18, "memberStandard": 15, "nsprefix": "BLNC", "nsuri": "http://balancelabs.co/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://balancelabs.co/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Stockholders\u2019 Equity", "menuCat": "Notes", "order": "10", "role": "http://balancelabs.co/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Note Receivable", "menuCat": "Notes", "order": "11", "role": "http://balancelabs.co/role/NoteReceivable", "shortName": "Note Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "12", "role": "http://balancelabs.co/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Convertible Notes and Notes Payable", "menuCat": "Notes", "order": "13", "role": "http://balancelabs.co/role/ConvertibleNotesAndNotesPayable", "shortName": "Convertible Notes and Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://balancelabs.co/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "15", "role": "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "16", "role": "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Related Party Transactions (Tables)", "menuCat": "Tables", "order": "17", "role": "http://balancelabs.co/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Convertible Notes and Notes Payable (Tables)", "menuCat": "Tables", "order": "18", "role": "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableTables", "shortName": "Convertible Notes and Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Going Concern (Details Narrative)", "menuCat": "Details", "order": "19", "role": "http://balancelabs.co/role/GoingConcernDetailsNarrative", "shortName": "Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "lang": null, "name": "BLNC:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://balancelabs.co/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EquityFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Schedule of Fair Value of Assets on Recurring Basis (Details)", "menuCat": "Details", "order": "20", "role": "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails", "shortName": "Schedule of Fair Value of Assets on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EquityFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Schedule of Property and Equipment (Details)", "menuCat": "Details", "order": "21", "role": "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CashEquivalentsAtCarryingValue", "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://balancelabs.co/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-10-03_custom_SammyFarkasFoundationIncMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Note Receivable (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://balancelabs.co/role/NoteReceivableDetailsNarrative", "shortName": "Note Receivable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "lang": null, "name": "BLNC:NotesReceivableUnamortizedAllowanceCurrentPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Schedule of Convertible Note Payable - Long Term (Details)", "menuCat": "Details", "order": "25", "role": "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails", "shortName": "Schedule of Convertible Note Payable - Long Term (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Schedule of Note Payable - Related Party (Details)", "menuCat": "Details", "order": "26", "role": "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails", "shortName": "Schedule of Note Payable - Related Party (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "BLNC:DueToRelatedPartyCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Schedule of Convertible Note Payable - Related Party (Details)", "menuCat": "Details", "order": "27", "role": "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails", "shortName": "Schedule of Convertible Note Payable - Related Party (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "BLNC:ConvertibleNotesPayableRelatedPartyTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_srt_ChiefExecutiveOfficerMember", "decimals": "0", "lang": null, "name": "BLNC:DueToRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2016-09-30_custom_BalanceGroupLLCMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Convertible Notes and Notes Payable (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "shortName": "Convertible Notes and Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_custom_ConvertibleDebentureMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://balancelabs.co/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://balancelabs.co/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://balancelabs.co/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30", "decimals": "0", "lang": null, "name": "BLNC:AccretedInterestOnNoteReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Business Organization and Nature of Operations", "menuCat": "Notes", "order": "7", "role": "http://balancelabs.co/role/BusinessOrganizationAndNatureOfOperations", "shortName": "Business Organization and Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Going Concern", "menuCat": "Notes", "order": "8", "role": "http://balancelabs.co/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://balancelabs.co/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 36, "tag": { "BLNC_AccountsPayableRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts payable related party current.", "label": "Accounts payable - related party" } } }, "localname": "AccountsPayableRelatedPartyCurrent", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BLNC_AccretedInterestIncomeAndInterestIncomeOnNoteReceivable": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accreted Interest Income And Interest Income On Note Receivable.", "label": "Accreted interest income and interest income on note receivable" } } }, "localname": "AccretedInterestIncomeAndInterestIncomeOnNoteReceivable", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "BLNC_AccretedInterestOnNoteReceivable": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accreted interest on note receivable.", "label": "AccretedInterestOnNoteReceivable", "negatedLabel": "Accreted interest on note receivable" } } }, "localname": "AccretedInterestOnNoteReceivable", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BLNC_BalanceGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance Group LLC [Member].", "label": "Balance Group LLC [Member]" } } }, "localname": "BalanceGroupLLCMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails", "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails" ], "xbrltype": "domainItemType" }, "BLNC_ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer And Company's Controlled By Chief Executive Officer [Member].", "label": "Chief Executive Officer and Company's Controlled by Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerAndCompanysControlledByChiefExecutiveOfficerMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Equipment & Software [Member]", "label": "Computer Equipment & Software [Member]" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "BLNC_ConvertibleDebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Debenture [Member].", "label": "Convertible Debenture [Member]" } } }, "localname": "ConvertibleDebentureMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_ConvertibleNotesPayableRelatedPartyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Payable Related Party [Table Text Block]", "label": "Schedule of Convertible Note Payable - Related Party" } } }, "localname": "ConvertibleNotesPayableRelatedPartyTableTextBlock", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "BLNC_DebtInstrumentExtendedMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, Extended maturity date.", "label": "Debt instrument maturity rate", "verboseLabel": "Debt instrument, extended maturity date" } } }, "localname": "DebtInstrumentExtendedMaturityDate", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "BLNC_DueToRelatedPartiesCurrentExcludeNotesPayableRelatedPartiesClassified": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short-term advances - related party.", "label": "Short -term advances - related party", "verboseLabel": "Short-term advances from related party" } } }, "localname": "DueToRelatedPartiesCurrentExcludeNotesPayableRelatedPartiesClassified", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/BalanceSheets", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BLNC_DueToRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Convertible notes payable - related party, net of debt discount of $0 and $0, as of June 30, 2023 and December 31, 2022", "verboseLabel": "Convertible note payable- related party" } } }, "localname": "DueToRelatedPartyCurrent", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/BalanceSheets", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "BLNC_EZFillHoldingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EZFill Holdings, Inc, [Member].", "label": "EZFill Holdings, Inc, [Member]" } } }, "localname": "EZFillHoldingsIncMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_EachAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Each Anniversary [Member]", "label": "Each Anniversary [Member]" } } }, "localname": "EachAnniversaryMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_EquityMethodInvestmentPercentageDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity method investment percentage, description.", "label": "Equity method investment percentage, description" } } }, "localname": "EquityMethodInvestmentPercentageDescription", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "BLNC_EquityMethodInvestmentSummarizedFinancialInformationNetLoss": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial Information net loss.", "label": "Net loss from equity method investment" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationNetLoss", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BLNC_FirstYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Year [Member]", "label": "First Year [Member]" } } }, "localname": "FirstYearMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_FoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundation [Member]", "label": "Foundation [Member]" } } }, "localname": "FoundationMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails" ], "xbrltype": "domainItemType" }, "BLNC_FourAcquisitionsLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Acquisitions Ltd [Member].", "label": "Four Acquisitions Ltd [Member]" } } }, "localname": "FourAcquisitionsLtdMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_IncreaseDecreaseInAccumulatedIncomeLossesOfUnconsolidatedInvesteesInExcessOfInvestment": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accumulated (income) losses on unconsolidated investees in excess of investment.", "label": "Accumulated losses on unconsolidated investees in excess of investment" } } }, "localname": "IncreaseDecreaseInAccumulatedIncomeLossesOfUnconsolidatedInvesteesInExcessOfInvestment", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BLNC_InvestmentAtFairValueReceivedFromIssuanceOfNoteReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment at fair value received from issuance of note receivable.", "label": "Investment at fair value received from issuance of note receivable" } } }, "localname": "InvestmentAtFairValueReceivedFromIssuanceOfNoteReceivable", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BLNC_InvestmentRelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment related parties.", "label": "Investments \u2013 Related Parties" } } }, "localname": "InvestmentRelatedPartiesPolicyTextBlock", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BLNC_KryptoVenturesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Krypto Ventures Inc [Member].", "label": "Krypto Ventures Inc [Member]" } } }, "localname": "KryptoVenturesIncMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_LyonsCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lyons Capital LLC [Member].", "label": "Lyons Capital LLC [Member]" } } }, "localname": "LyonsCapitalLLCMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_MonthlyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Monthly [Member]", "label": "Monthly [Member]" } } }, "localname": "MonthlyMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_NewellTradingGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Newell Trading Group [Member]", "label": "Newell Trading Group [Member]" } } }, "localname": "NewellTradingGroupMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsTables" ], "xbrltype": "domainItemType" }, "BLNC_NotesPayableUnamortizedDiscountCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable unamortized discount current.", "label": "Notes payable - related party, debt discount - current" } } }, "localname": "NotesPayableUnamortizedDiscountCurrent", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "BLNC_NotesReceivableUnamortizedAllowanceCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Notes receivable unamortized allowance current.", "label": "Notes receivable unamortized allowance current" } } }, "localname": "NotesReceivableUnamortizedAllowanceCurrent", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BLNC_NotesReceivableUnamortizedAllowanceCurrentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes receivable unamortized allowance current, percentage.", "label": "Notes receivable unamortized allowance current, percentage" } } }, "localname": "NotesReceivableUnamortizedAllowanceCurrentPercentage", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "percentItemType" }, "BLNC_NumberOfSharesExchange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares exchange.", "label": "Number of shares exchange" } } }, "localname": "NumberOfSharesExchange", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BLNC_NumberOfWarrantsIssuedToRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued to related party.", "label": "Number of warrants issued to related party" } } }, "localname": "NumberOfWarrantsIssuedToRelatedParty", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BLNC_PharmacyNo27LtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy No 27 Ltd [Member]", "label": "Pharmacy No 27 Ltd [Member]" } } }, "localname": "PharmacyNo27LtdMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member].", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_SammyFarkasFoundationIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sammy Farkas Foundation Inc [Member]", "label": "Sammy Farkas Foundation Inc. [Member]" } } }, "localname": "SammyFarkasFoundationIncMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_SecondYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Year [Member]", "label": "Second Year [Member]" } } }, "localname": "SecondYearMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BLNC_SellingGeneralAndAdministrativeExpensesRelatedAndNonrelatedParty": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Selling general and administrative expenses related and nonrelated party.", "label": "General and administrative expenses - related party" } } }, "localname": "SellingGeneralAndAdministrativeExpensesRelatedAndNonrelatedParty", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "BLNC_UnrealizedLossOnInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrealized loss on investments.", "label": "Unrealized loss on investments" } } }, "localname": "UnrealizedLossOnInvestments", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BLNC_WebsiteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Website [Member]", "label": "Website [Member]" } } }, "localname": "WebsiteMember", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "BLNC_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "WorkingCapitalDeficit", "negatedLabel": "Working capital" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://balancelabs.co/20230630", "presentation": [ "http://balancelabs.co/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r535", "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://balancelabs.co/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r138", "r307", "r308", "r309", "r310", "r346", "r487", "r565", "r568", "r569" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r138", "r307", "r308", "r309", "r310", "r346", "r487", "r565", "r568", "r569" ], "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r191", "r192", "r193" ], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r207", "r208", "r209", "r210", "r280", "r351", "r383", "r405", "r406", "r468", "r474", "r475", "r476", "r479", "r488", "r489", "r497", "r503", "r509", "r511", "r570", "r605", "r606", "r607", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r207", "r208", "r209", "r210", "r280", "r351", "r383", "r405", "r406", "r468", "r474", "r475", "r476", "r479", "r488", "r489", "r497", "r503", "r509", "r511", "r570", "r605", "r606", "r607", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r207", "r208", "r209", "r210", "r272", "r280", "r287", "r288", "r289", "r350", "r351", "r383", "r405", "r406", "r468", "r474", "r475", "r476", "r479", "r488", "r489", "r497", "r503", "r509", "r511", "r514", "r563", "r570", "r606", "r607", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r207", "r208", "r209", "r210", "r272", "r280", "r287", "r288", "r289", "r350", "r351", "r383", "r405", "r406", "r468", "r474", "r475", "r476", "r479", "r488", "r489", "r497", "r503", "r509", "r511", "r514", "r563", "r570", "r606", "r607", "r608", "r609", "r610" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r152", "r281", "r544", "r556" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r152", "r281", "r544", "r545", "r556" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r559", "r601" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r10", "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable related party" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r185", "r186" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r30", "r117", "r376" ], "calculation": { "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r65", "r510", "r617" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r291", "r292", "r293", "r399", "r553", "r554", "r555", "r598", "r621" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operations" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising, Marketing and Promotional Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r3", "r43", "r74", "r242" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from earnings per share amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r118", "r135", "r163", "r176", "r180", "r194", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r307", "r309", "r328", "r369", "r428", "r510", "r523", "r566", "r567", "r603" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r113", "r119", "r135", "r194", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r307", "r309", "r328", "r510", "r566", "r567", "r603" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r306", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r36", "r37", "r306", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Equity interest acquire percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r21", "r115", "r491" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets", "http://balancelabs.co/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r21", "r75", "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r75" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r546", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants issued to purchase of common stock shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r18", "r52", "r370", "r414" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r82", "r205", "r206", "r486", "r564" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r512", "r513", "r514", "r516", "r517", "r518", "r519", "r553", "r554", "r598", "r614", "r621" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r64", "r415" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r64", "r415", "r434", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r64", "r372", "r510" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value: authorized 500,000,000, 21,674,000 and 21,674,000 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r55", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r40", "r492" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Schedule of Convertible Note Payable - Long Term" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableTables", "http://balancelabs.co/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r17" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible note payable, net of debt discount of $14,175 and $19,845 as of June 30, 2023 and December 31, 2022", "totalLabel": "Convertible note payable \u2013 long term" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r9", "r92", "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible note payable", "verboseLabel": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r60", "r91" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r83", "r133", "r220", "r226", "r227", "r228", "r229", "r230", "r231", "r236", "r243", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Convertible Notes and Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r9", "r60", "r61", "r91", "r92", "r138", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r336", "r498", "r499", "r500", "r501", "r502", "r551" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt instrument, convertible, beneficial conversion", "verboseLabel": "Debt Instrument, Convertible, Beneficial Conversion Feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r84", "r223" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt instrument convertible conversion price", "verboseLabel": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r44", "r47", "r221", "r336", "r499", "r500" ], "calculation": { "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, face amount", "terseLabel": "Convertible note payable \u2013 long term, gross", "verboseLabel": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r551" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r551" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.", "label": "Debt instrument, increase (decrease), net", "verboseLabel": "Debt Instrument, Increase (Decrease), Net" } } }, "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r16", "r222" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate of related party loan", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Debt instrument interest rate stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/NoteReceivableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r108", "r498", "r599" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt maturity date", "terseLabel": "Debt Instrument, Maturity Date", "verboseLabel": "Debt instrument maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/NoteReceivableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r17", "r138", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r336", "r498", "r499", "r500", "r501", "r502", "r551" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r43", "r47", "r571" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt instrument discount", "verboseLabel": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r43", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt instrument, unamortized discount, current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r43", "r47" ], "calculation": { "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Convertible notes payable, debt discount - long term", "negatedLabel": "Debt discount", "terseLabel": "Debt Instrument, Unamortized Discount, Noncurrent", "verboseLabel": "Debt instrument unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical", "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-LongTermDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r43", "r44", "r45", "r46", "r47", "r571" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [ "r560", "r561" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "negatedLabel": "Unrealized (gain) loss on available - for - sale securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r382", "r549", "r550" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Unrealized loss on securities" } } }, "localname": "DebtSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r3", "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r127", "r144", "r145", "r146", "r147", "r148", "r153", "r155", "r157", "r158", "r159", "r161", "r319", "r320", "r365", "r380", "r493" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net Loss per share - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r127", "r144", "r145", "r146", "r147", "r148", "r155", "r157", "r158", "r159", "r161", "r319", "r320", "r365", "r380", "r493" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net Loss per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r24", "r25" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income (Loss) Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r110", "r123", "r124", "r125", "r139", "r140", "r141", "r143", "r149", "r151", "r162", "r195", "r196", "r261", "r291", "r292", "r293", "r304", "r305", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r329", "r330", "r331", "r332", "r333", "r334", "r337", "r384", "r385", "r386", "r399", "r460" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFairValueDisclosure": { "auth_ref": [ "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the entity's equity.", "label": "Fair-value - equity securities" } } }, "localname": "EquityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r0", "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r322", "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r322", "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r42", "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value of Assets on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r234", "r273", "r274", "r275", "r276", "r277", "r278", "r323", "r347", "r348", "r349", "r499", "r500", "r504", "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r322", "r323", "r324", "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r234", "r273", "r278", "r323", "r347", "r504", "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r234", "r273", "r278", "r323", "r348", "r499", "r500", "r504", "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r234", "r273", "r274", "r275", "r276", "r277", "r278", "r323", "r349", "r499", "r500", "r504", "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r234", "r273", "r274", "r275", "r276", "r277", "r278", "r347", "r348", "r349", "r499", "r500", "r504", "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r321", "r327" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfFairValueOfAssetsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r5", "r8" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r3" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Proceeds from sale of investment" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72", "r439" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r3", "r68", "r94", "r167", "r190", "r378" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Net loss allocated from equity method investees" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r122", "r298", "r299", "r300", "r301", "r302", "r303", "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income tax" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r2" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "auth_ref": [ "r2" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Accounts receivable \u2013 related party" } } }, "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r2" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Interest receivable" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r2" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Accounts payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Decrease (Increase) in" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase in" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r45", "r96", "r126", "r166", "r335", "r445", "r521", "r618" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense (includes amortization of debt discount)" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r71", "r437", "r481", "r482", "r520", "r521", "r623" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest income related party" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r128", "r129", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r50", "r611" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest payable current and noncurrent", "verboseLabel": "Interest Payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r389", "r402", "r403", "r470", "r473", "r478", "r483", "r514", "r523", "r615" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Investment Owned, Cost", "verboseLabel": "Fair value of investment cost" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r401", "r404", "r469", "r477", "r480", "r514" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of investment owned.", "label": "Fair value of investment cost" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r381", "r389", "r390", "r391", "r392", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments [Default Label]", "verboseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments fair value disclosure" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r135", "r194", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r308", "r309", "r310", "r328", "r413", "r494", "r523", "r566", "r603", "r604" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r67", "r93", "r374", "r510", "r552", "r562", "r600" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r114", "r135", "r194", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r308", "r309", "r310", "r328", "r510", "r566", "r603", "r604" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r9", "r57", "r58", "r59", "r62", "r135", "r194", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r308", "r309", "r310", "r328", "r566", "r603", "r604" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total Long-Term Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Note Receivable" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r9", "r92", "r233", "r246", "r499", "r500", "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r53", "r547" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities [Default Label]", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r547" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r70" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Unrealized gain (loss) on available for sale securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Advertising, marketing and promotion expense" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r75", "r76", "r77" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash provided (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/GoingConcernDetailsNarrative", "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r69", "r77", "r95", "r112", "r120", "r121", "r125", "r135", "r142", "r144", "r145", "r146", "r147", "r150", "r151", "r156", "r163", "r175", "r179", "r181", "r194", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r320", "r328", "r379", "r436", "r458", "r459", "r495", "r521", "r566" ], "calculation": { "http://balancelabs.co/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://balancelabs.co/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows", "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit", "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Note Payable \u2013 related party" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r185", "r197", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Officers compensation" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and expenses" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r163", "r175", "r179", "r181", "r495" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r78", "r79", "r80", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Business Organization and Nature of Operations" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BusinessOrganizationAndNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r51", "r367", "r409", "r410", "r523", "r616" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Due to related parties" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Notes payable - related party - net of debt discount of $0 and $0 as of June 30, 2023 and December 31, 2022" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r63", "r248" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r63", "r415" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r63", "r248" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r63", "r415", "r434", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r63", "r371", "r510" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value, 50,000,000 shares authorized, none issued and outstanding as of June 30, 2023 and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible debt", "verboseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r521", "r619", "r620" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r81", "r116", "r377" ], "calculation": { "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r4", "r366", "r377", "r510" ], "calculation": { "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r4", "r104", "r107", "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, plant and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r279", "r341", "r342", "r408", "r409", "r410", "r411", "r412", "r433", "r435", "r467" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r136", "r137", "r341", "r342", "r343", "r344", "r408", "r409", "r410", "r411", "r412", "r433", "r435", "r467" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r341", "r342", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsTables", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails", "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsTables", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails", "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r440", "r441", "r444" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsTables", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails", "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r279", "r341", "r342", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r408", "r409", "r410", "r411", "r412", "r433", "r435", "r467", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StockholdersEquityDetailsNarrative", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r338", "r339", "r340", "r342", "r345", "r395", "r396", "r397", "r442", "r443", "r444", "r464", "r466" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [ "r198", "r199", "r200", "r201", "r202", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r66", "r86", "r373", "r387", "r388", "r394", "r416", "r510" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets", "http://balancelabs.co/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r110", "r139", "r140", "r141", "r143", "r149", "r151", "r195", "r196", "r291", "r292", "r293", "r304", "r305", "r311", "r313", "r314", "r316", "r318", "r384", "r386", "r399", "r621" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r164", "r165", "r174", "r177", "r178", "r182", "r183", "r184", "r270", "r271", "r352" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues - related party" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r109", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r490" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r548" ], "calculation": { "http://balancelabs.co/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and wages" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Note Payable - Related Party" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r6", "r32", "r33", "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ScheduleOfPropertyAndEquipmentDetails", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r48", "r49", "r440", "r441", "r444" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/RelatedPartyTransactionsTables", "http://balancelabs.co/role/ScheduleOfConvertibleNotePayable-RelatedPartyDetails", "http://balancelabs.co/role/ScheduleOfNotePayable-RelatedPartyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r198", "r199", "r200", "r201", "r202", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/NoteReceivableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r183", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Business Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "General and administrative expenses - related party" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287", "r290", "r294", "r295", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued price, per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/ConvertibleNotesAndNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r78", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r19", "r110", "r123", "r124", "r125", "r139", "r140", "r141", "r143", "r149", "r151", "r162", "r195", "r196", "r261", "r291", "r292", "r293", "r304", "r305", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r329", "r330", "r331", "r332", "r333", "r334", "r337", "r384", "r385", "r386", "r399", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r139", "r140", "r141", "r162", "r352", "r389", "r400", "r407", "r408", "r409", "r410", "r411", "r412", "r415", "r418", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r435", "r438", "r439", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r515" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r139", "r140", "r141", "r162", "r352", "r389", "r400", "r407", "r408", "r409", "r410", "r411", "r412", "r415", "r418", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r435", "r438", "r439", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r515" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r38", "r39", "r41", "r110", "r111", "r124", "r139", "r140", "r141", "r143", "r149", "r195", "r196", "r261", "r291", "r292", "r293", "r304", "r305", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r329", "r330", "r334", "r337", "r385", "r386", "r398", "r417", "r434", "r461", "r462", "r484", "r522", "r552", "r562", "r600", "r621" ], "calculation": { "http://balancelabs.co/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/BalanceSheets", "http://balancelabs.co/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r85", "r134", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r317", "r463", "r465", "r485" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r97", "r98", "r99", "r187", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r9", "r92", "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r26", "r27", "r28", "r101", "r102", "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r512", "r513", "r516", "r517", "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/RelatedPartyTransactionsDetailsNarrative", "http://balancelabs.co/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r154", "r159" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of shares - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r153", "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://balancelabs.co/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "39", "Publisher": "FASB", "Section": "45", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r532": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r533": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r534": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r535": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r536": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r537": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r538": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r539": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r541": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r542": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r543": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//310-10/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" } }, "version": "2.2" } ZIP 48 0001493152-23-027864-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-027864-xbrl.zip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�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